Bruker (BRKR) 10-Q 4 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Oct. 30, 2019
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2019
Document Transition Report	false
Entity File Number	000-30833
Entity Registrant Name	BRUKER CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3110160
Entity Address, Address Line One	40 Manning Road
Entity Address, City or Town	Billerica
Entity Address, Postal Zip Code	01821
Entity Address, State or Province	MA
City Area Code	978
Local Phone Number	663-3660
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Trading Symbol	BRKR
Security Exchange Name	NASDAQ
Title of 12(b) Security	Common Stock
Entity Common Stock, Shares Outstanding		153,991,644
Entity Central Index Key	0001109354
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false

UNAUDITED CONDENSED CONSOLIDATE

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 296.3	$ 322.4
Short-term investments	6.1
Accounts receivable, net	358.8	357.2
Inventories	586.7	509.6
Other current assets	186.1	115.1
Total current assets	1,434	1,304.3
Property, plant and equipment, net	278.1	270.6
Goodwill	282.3	275.7
Operating lease assets	68.9
Intangibles, net and other long-term assets	288.8	278
Total assets	2,352.1	2,128.6
Current liabilities:
Current portion of long-term debt	0.3	18.5
Accounts payable	116.6	104.5
Customer advances	126.1	124.4
Other current liabilities	400	351.9
Total current liabilities	643	599.3
Long-term debt	518.5	322.6
Operating lease liabilities	50.7
Other long-term liabilities	264.3	279
Commitments and contingencies (Note 13)
Redeemable noncontrolling interest	20.9	22.6
Shareholders' equity:
Preferred stock, $0.01 par value 5,000,000 shares authorized, none issued or outstanding
Common stock, $0.01 par value 260,000,000 shares authorized, 173,292,361 and 172,634,220 shares issued and 153,945,784 and 156,609,340 shares outstanding at September 30, 2019 and December 31, 2018, respectively	1.7	1.7
Treasury stock, at cost, 19,346,577 and 16,024,880 shares at September 30, 2019 and December 31, 2018, respectively	(543.8)	(401.5)
Accumulated other comprehensive income	(18.8)	17
Other shareholders' equity	1,406.1	1,279.4
Total shareholders' equity attributable to Bruker Corporation	845.2	896.6
Noncontrolling interest in consolidated subsidiaries	9.5	8.5
Total shareholders' equity	854.7	905.1
Total liabilities and shareholders' equity	$ 2,352.1	$ 2,128.6

UNAUDITED CONDENSED CONSOLIDA_2

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	260,000,000	260,000,000
Common stock, shares issued	173,292,361	172,634,220
Common stock, shares outstanding	153,945,784	156,609,340
Treasury stock, shares	19,346,577	16,024,880

UNAUDITED CONDENSED CONSOLIDA_3

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenue	$ 521.1	$ 466.6	$ 1,472.7	$ 1,342
Cost of revenue	267.2	244	773.7	714.8
Gross profit	253.9	222.6	699	627.2
Operating expenses:
Selling, general and administrative	125.3	106.5	369.9	327.4
Research and development	46.1	41.8	141	128.6
Other charges (gain), net	(5.3)	5.2	4.9	15.2
Total operating expenses	166.1	153.5	515.8	471.2
Operating income	87.8	69.1	183.2	156
Interest and other income (expense), net	(4.6)	(3.7)	(14)	(11.5)
Income before income taxes and noncontrolling interest in consolidated subsidiaries	83.2	65.4	169.2	144.5
Income tax provision	21.7	21.2	40	41.4
Consolidated net income	61.5	44.2	129.2	103.1
Net income attributable to noncontrolling interests in consolidated subsidiaries	0.2	0.8	0.6	1.5
Net income attributable to Bruker Corporation	$ 61.3	$ 43.4	$ 128.6	$ 101.6
Net income per common share attributable to Bruker Corporation shareholders:
Basic (in dollars per share)	$ 0.40	$ 0.28	$ 0.83	$ 0.65
Diluted (in dollars per share)	$ 0.39	$ 0.28	$ 0.82	$ 0.65
Weighted average common shares outstanding:
Basic (in shares)	154.2	156.4	155.7	156.1
Diluted (in shares)	155.6	157.4	157	157.2
Comprehensive income (loss)	$ 26.1	$ 41.9	$ 92	$ 88.3
Less: Comprehensive income (loss) attributable to noncontrolling interests	0.2	0.5	1	0.9
Less: Comprehensive income (loss) attributable to redeemable noncontrolling interest	(1.2)		(1.8)
Comprehensive income (loss) attributable to Bruker Corporation	$ 27.1	$ 41.4	$ 92.8	$ 87.4
Dividend declared per common share (in dollars per share)	$ 0.04	$ 0.04	$ 0.12	$ 0.12
Product
Revenue	$ 440.6	$ 385.5	$ 1,235.3	$ 1,105.8
Cost of revenue	220.4	197.3	627.9	571.6
Service
Revenue	78.8	79.6	234.8	230.8
Cost of revenue	46.5	46.6	145.3	142.2
Other
Revenue	1.7	1.5	2.6	5.4
Cost of revenue	$ 0.3	$ 0.1	$ 0.5	$ 1

UNAUDITED CONDENSED CONSOLIDA_4

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND SHAREHOLDERS' EQUITY - USD ($) $ in Millions	Total Shareholders' Equity Attributable to Bruker Corporation	Common Stock	Treasury Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interests in Consolidated Subsidiaries	Redeemable Noncontrolling Interest	Total
Balance at beginning of period at Dec. 31, 2017	$ 725.4	$ 1.7	$ (401.2)	$ 155.9	$ 942	$ 27	$ 8.1		$ 733.5
Balance (in shares) at Dec. 31, 2017		155,865,977	16,009,099
Increase (Decrease) in Stockholders' Equity
Restricted shares terminated (in shares)		(6,553)	6,553
Stock options exercised	2.9			2.9					2.9
Stock options exercised (in shares)		180,890
Restricted stock units vested (in shares)		42,762
Stock based compensation	2.5			2.5					2.5
Shares issued for acquisition	(0.1)		$ (0.1)						(0.1)
Shares issued for acquisition (in shares)		(2,123)	2,123
Treasury stock acquired (in shares)		(1,055)	1,055
Adoption impact from new revenue standard ASC 606	5.9				5.9		0.2		6.1
Cash dividends paid to common stockholders	(6.3)				(6.3)				(6.3)
Consolidated net income (loss)	27				27		0.4		27.4
Other comprehensive income (loss)	24.2					24.2	0.1		24.3
Balance at end of period at Mar. 31, 2018	781.5	$ 1.7	$ (401.3)	161.3	968.6	51.2	8.8		790.3
Balance (in shares) at Mar. 31, 2018		156,079,898	16,018,830
Balance at beginning of period at Dec. 31, 2017	725.4	$ 1.7	$ (401.2)	155.9	942	27	8.1		733.5
Balance (in shares) at Dec. 31, 2017		155,865,977	16,009,099
Balance at end of period at Sep. 30, 2018	816.9	$ 1.7	$ (401.5)	173.3	1,030.7	12.7	8.3		825.2
Balance (in shares) at Sep. 30, 2018		156,512,202	16,024,880
Balance at beginning of period at Mar. 31, 2018	781.5	$ 1.7	$ (401.3)	161.3	968.6	51.2	8.8		790.3
Balance (in shares) at Mar. 31, 2018		156,079,898	16,018,830
Increase (Decrease) in Stockholders' Equity
Stock options exercised	4.2			4.2					4.2
Stock options exercised (in shares)		221,464
Restricted stock units vested (in shares)		5,964
Stock based compensation	2.4			2.4					2.4
Treasury stock acquired	(0.1)		$ (0.1)						(0.1)
Treasury stock acquired (in shares)		(1,384)	1,384
Cash dividends paid to common stockholders	(6.2)				(6.2)				(6.2)
Consolidated net income (loss)	31.2				31.2		0.3		31.5
Other comprehensive income (loss)	(36.4)					(36.4)	(0.4)		(36.8)
Balance at end of period at Jun. 30, 2018	776.6	$ 1.7	$ (401.4)	167.9	993.6	14.8	8.7		785.3
Balance (in shares) at Jun. 30, 2018		156,305,942	16,020,214
Increase (Decrease) in Stockholders' Equity
Stock options exercised	2.5			2.5					2.5
Stock options exercised (in shares)		127,003
Restricted stock units vested	(0.4)			(0.4)					(0.4)
Restricted stock units vested (in shares)		83,923
Stock based compensation	3.3			3.3					3.3
Treasury stock acquired	(0.1)		$ (0.1)						(0.1)
Treasury stock acquired (in shares)		(4,666)	4,666
Distributions to noncontrolling interests							(0.9)		(0.9)
Cash dividends paid to common stockholders	(6.3)				(6.3)				(6.3)
Consolidated net income (loss)	43.4				43.4		0.7		44.1
Other comprehensive income (loss)	(2.1)					(2.1)	(0.2)		(2.3)
Balance at end of period at Sep. 30, 2018	816.9	$ 1.7	$ (401.5)	173.3	1,030.7	12.7	8.3		825.2
Balance (in shares) at Sep. 30, 2018		156,512,202	16,024,880
Balance at beginning of period at Dec. 31, 2018	896.6	$ 1.7	$ (401.5)	176.9	1,102.5	17	8.5	$ 22.6	905.1
Balance (in shares) at Dec. 31, 2018		156,609,340	16,024,880
Increase (Decrease) in Stockholders' Equity
Stock options exercised	3.1			3.1					3.1
Stock options exercised (in shares)		167,177
Restricted stock units vested (in shares)		35,072
Stock based compensation	2.7			2.7					2.7
Shares issued for acquisition (in shares)		3,087	(3,087)
Cash dividends paid to common stockholders	(6.3)				(6.3)				(6.3)
Consolidated net income (loss)	30.8				30.8		0.1	(0.2)	30.9
Other comprehensive income (loss)	(13.7)					(13.7)	(0.2)	(0.4)	(13.9)
Balance at end of period at Mar. 31, 2019	913.2	$ 1.7	$ (401.5)	182.7	1,127	3.3	8.4	22	921.6
Balance (in shares) at Mar. 31, 2019		156,814,676	16,021,793
Balance at beginning of period at Dec. 31, 2018	896.6	$ 1.7	$ (401.5)	176.9	1,102.5	17	8.5	22.6	905.1
Balance (in shares) at Dec. 31, 2018		156,609,340	16,024,880
Balance at end of period at Sep. 30, 2019	845.2	$ 1.7	$ (543.8)	193.8	1,212.3	(18.8)	9.5	20.9	854.7
Balance (in shares) at Sep. 30, 2019		153,945,784	19,346,577
Balance at beginning of period at Mar. 31, 2019	913.2	$ 1.7	$ (401.5)	182.7	1,127	3.3	8.4	22	921.6
Balance (in shares) at Mar. 31, 2019		156,814,676	16,021,793
Increase (Decrease) in Stockholders' Equity
Stock options exercised	2.7			2.7					2.7
Stock options exercised (in shares)		145,606
Restricted stock units vested (in shares)		2,344
Stock based compensation	2.6			2.6					2.6
Shares repurchased	(100)		$ (100)						(100)
Shares repurchased (in shares)		(2,300,635)	2,300,635
Cash dividends paid to common stockholders	(6.3)				(6.3)				(6.3)
Consolidated net income (loss)	36.5				36.5		0.8	(0.3)	37.3
Other comprehensive income (loss)	12.1					12.1	0.1	0.3	12.2
Balance at end of period at Jun. 30, 2019	860.8	$ 1.7	$ (501.5)	188	1,157.2	15.4	9.3	22	870.1
Balance (in shares) at Jun. 30, 2019		154,661,991	18,322,428
Increase (Decrease) in Stockholders' Equity
Stock options exercised	3.1			3.1					3.1
Stock options exercised (in shares)		152,918
Restricted stock units vested	(0.8)			(0.8)					(0.8)
Restricted stock units vested (in shares)		155,024
Stock based compensation	3.5			3.5					3.5
Shares repurchased	(42.3)		$ (42.3)						(42.3)
Shares repurchased (in shares)		(1,022,469)	1,022,469
Treasury stock acquired (in shares)		(1,680)	1,680
Cash dividends paid to common stockholders	(6.2)				(6.2)				(6.2)
Consolidated net income (loss)	61.3				61.3		0.4	(0.2)	61.7
Other comprehensive income (loss)	(34.2)					(34.2)	(0.2)	(0.9)	(34.4)
Balance at end of period at Sep. 30, 2019	$ 845.2	$ 1.7	$ (543.8)	$ 193.8	$ 1,212.3	$ (18.8)	$ 9.5	$ 20.9	$ 854.7
Balance (in shares) at Sep. 30, 2019		153,945,784	19,346,577

UNAUDITED CONDENSED CONSOLIDA_5

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Consolidated net income	$ 129.2	$ 103.1
Adjustments to reconcile consolidated net income to cash flows from operating activities:
Depreciation and amortization	57.3	48.3
Stock-based compensation expense	10.1	8.2
Deferred income taxes	(0.5)	(8.6)
Other non-cash expenses, net	1.7	28.7
Changes in operating assets and liabilities, net of acquisitions and divestitures:
Accounts receivable	(8)	(6.9)
Inventories	(80.9)	(55.3)
Accounts payable and accrued expenses	10.3	(1.2)
Income taxes payable, net	(6.4)	(8.5)
Deferred revenue	9.7	4.8
Customer advances	(9.1)	2.1
Other changes in operating assets and liabilities, net	(36.2)	(7.3)
Net cash provided by operating activities	77.2	107.4
Cash flows from investing activities:
Purchases of short-term investments	(6.4)
Maturities of short-term investments		117
Cash paid for acquisitions, net of cash acquired	(79)	(55.3)
Purchases of property, plant and equipment	(44.8)	(28.9)
Proceeds from sales of property, plant and equipment	11	0.1
Net cash (used in) provided by investing activities	(119.2)	32.9
Cash flows from financing activities:
Repayments of Note Purchase Agreement	(15)
Repayments of revolving lines of credit	(50.5)	(202.5)
Proceeds from revolving lines of credit	250.6	27.5
Repayment of other debt	(4.8)	(0.9)
Proceeds of other debt	0.4
Proceeds from issuance of common stock, net	8.1	8.9
Payment of contingent consideration	(5.6)	(2.3)
Repurchase of common stock	(142.3)
Payment of dividends	(18.8)	(18.8)
Cash payments to noncontrolling interest		(0.9)
Net cash provided by (used in) financing activities	22.1	(189)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(6.4)	(5.4)
Net change in cash, cash equivalents and restricted cash	(26.3)	(54.1)
Cash, cash equivalents and restricted cash at beginning of period	326.3	328.9
Cash, cash equivalents and restricted cash at end of period	$ 300	$ 274.8

Description of Business

Description of Business	9 Months Ended
	Sep. 30, 2019
Description of Business
Description of Business	1. Description of Business ​ Bruker Corporation, together with its consolidated subsidiaries (Bruker or the Company), develops, manufactures and distributes high-performance scientific instruments and analytical and diagnostic solutions that enable its customers to explore life and materials at microscopic, molecular and cellular levels. Many of the Company’s products are used to detect, measure and visualize structural characteristics of chemical, biological and industrial material samples. The Company’s products address the rapidly evolving needs of a diverse array of customers in life science research, pharmaceuticals, biotechnology, applied markets, cell biology, clinical research, microbiology, in-vitro diagnostics, nanotechnology and materials science research. ​ The Company has two reportable segments, Bruker Scientific Instruments (BSI) Bruker Energy & Supercon Technologies (BEST) , which represented the remainder of the Company’s revenues. Within BSI, the Company is organized into three operating segments: the Bruker BioSpin Group, the Bruker CALID Group and the Bruker Nano Group. For financial reporting purposes, the Bruker BioSpin Group, Bruker CALID Group and Bruker Nano Group operating segments are aggregated into the BSI reportable segment because each has similar economic characteristics, production processes, service offerings, types and classes of customers, methods of distribution and regulatory environments. ​ Bruker BioSpin ​ Bruker CALID (Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection) - The Bruker CALID Group designs, manufactures and distributes life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies and radiological/nuclear detectors for Chemical, Biological, Radiological, Nuclear and Explosive (CBRNE) detection. Customers of the Bruker CALID Group include: academic institutions and medical schools; pharmaceutical, biotechnology and diagnostics companies; contract research organizations; nonprofit and for-profit forensics laboratories; agriculture, food and beverage safety laboratories; environmental and clinical microbiology laboratories; hospitals and government departments and agencies. ​ Bruker Nano ​ The Company's BEST reportable segment develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare and "big science" research. The segment focuses on metallic low temperature superconductors for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research and other applications. ​ The unaudited condensed consolidated financial statements represent the consolidated accounts of the Company. All intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements as of September 30, 2019 and December 31, 2018, and for the three and nine months ended September 30, 2019 and 2018, have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) for Quarterly Reports on Form 10-Q and Article 10 of Regulation S-X. Accordingly, the financial information presented herein does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair statement have been included. The results for interim periods are not necessarily indicative of the results expected for any other interim period or the full year. ​ At September 30, 2019, the Company's significant accounting policies and estimates, which are detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2018, have not changed other than for lease accounting as detailed in Footnote 14.

Revenue

Revenue	9 Months Ended
	Sep. 30, 2019
Revenue
Revenue	2. Revenue ​ The following table presents the Company’s revenues by Group and End Customer Geography (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, ​ 2019 2018 2019 2018 Revenue by Group: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Bruker BioSpin $ 143.7 ​ $ 139.5 $ 422.4 ​ $ 411.2 Bruker CALID ​ 158.2 ​ ​ 134.6 ​ 446.9 ​ ​ 393.9 Bruker Nano ​ 169.9 ​ ​ 143.0 ​ 461.7 ​ ​ 401.4 BEST ​ 52.5 ​ ​ 50.9 ​ 152.2 ​ ​ 139.2 Eliminations ​ (3.2) ​ ​ (1.4) ​ (10.5) ​ ​ (3.7) Total revenue ​ $ 521.1 ​ $ 466.6 ​ $ 1,472.7 ​ $ 1,342.0 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, ​ 2019 2018 2019 2018 Revenue by End Customer Geography: ​ ​ ​ ​ ​ ​ ​ ​ United States $ 135.5 ​ $ 134.1 $ 379.3 ​ $ 347.3 Germany ​ 57.7 ​ ​ 44.9 ​ 150.1 ​ ​ 135.3 Rest of Europe ​ 121.0 ​ ​ 114.6 ​ 350.0 ​ ​ 346.4 Asia Pacific ​ 158.5 ​ ​ 134.4 ​ 464.5 ​ ​ 396.8 Other ​ 48.4 ​ ​ 38.6 ​ 128.8 ​ ​ 116.2 Total revenue ​ $ 521.1 ​ $ 466.6 ​ $ 1,472.7 ​ $ 1,342.0 ​ Revenue for the Company recognized at a point in time versus over time is as follows (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, ​ 2019 2018 2019 2018 Revenue recognized at a point in time $ 463.8 ​ $ 427.1 $ 1,310.2 ​ $ 1,227.6 Revenue recognized over time ​ 57.3 ​ ​ 39.5 ​ 162.5 ​ ​ 114.4 Total revenue $ 521.1 ​ $ 466.6 $ 1,472.7 ​ $ 1,342.0 ​ Remaining Performance Obligations ​ Remaining performance obligations represent the aggregate transaction price allocated to a promise to transfer a good or service that is fully or partially unsatisfied at the end of the period. As of September 30, 2019, remaining performance obligations were approximately $1,520.5 million. The Company expects to recognize revenue on approximately 63.6% of the remaining performance obligations over the next twelve months and the remaining performance obligations primarily within one to five years . ​ Contract Balances ​ The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets) and deferred revenue, customer deposits and billings in excess of revenue recognized (contract liabilities) on the Company’s unaudited condensed consolidated balance sheets. ​ Contract assets— million, respectively. The increase in the contract asset balance during the nine month period ended September 30, 2019 is primarily a result of foreign currency translation and contracts that have been recognized as revenue during the nine month period ending September 30, 2019 for which billing cannot contractually occur as of September 30, 2019. ​ Contract liabilities— The Company often receives cash payments from customers in advance of the Company’s performance, resulting in contract liabilities. These contract liabilities are classified as either current or long-term in the unaudited condensed consolidated balance sheet based on the timing of when revenue recognition is expected. As of September 30, 2019 and December 31, 2018, the contract liabilities were $295.1 million and $288.5 million, respectively. The increase in the contract liability balance during the nine month period ended September 30, 2019 is primarily a result of new performance obligations entered into during the nine month period. Approximately $165.0 million of the contract liability balance on December 31, 2018 was recognized as revenue during the nine month period ended September 30, 2019 .

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2019
Acquisitions
Acquisitions	3. Acquisitions ​ The impact of all acquisitions, individually and collectively, on revenues, net income and total assets was not material. Pro forma financial information reflecting all acquisitions has not been presented because the impact, individually and collectively, on revenues, net income and total assets is not material. Amounts allocated to goodwill that are attributable to expected synergies are not expected to be deductible for tax purposes. ​ 2019 ​ On April 2, 2019, the Company acquired Rave LLC (“Rave”), a privately held company, for a purchase price of $52.2 million with the potential for additional consideration of up to $5.0 million based on revenue and gross margin achievements in 2019 and 2020. Rave develops and manufactures nanomachining and laser photomask repair equipment. Rave was integrated into the Bruker Nano Group within the BSI reportable segment. The acquisition of Rave was accounted for under the acquisition method. The components and fair value allocation of the consideration transferred in connection with the acquisition were as follows (dollars in millions): ​ ​ ​ ​ ​ Consideration Transferred: ​ Cash paid $ 55.8 Contingent consideration ​ 4.4 Working capital adjustment ​ ​ (3.6) Total consideration transferred ​ $ 56.6 ​ ​ ​ ​ Allocation of Consideration Transferred: ​ Inventories ​ $ 23.1 Accounts receivable ​ 2.2 Other current and non-current assets ​ 0.8 Property, plant and equipment ​ 2.1 Operating lease assets ​ 1.0 Intangible assets: ​ ​ Technology ​ 17.9 Customer relationships ​ 15.5 Trade name ​ 1.5 Goodwill ​ 6.4 Liabilities assumed ​ (13.9) Total consideration allocated ​ $ 56.6 ​ The preliminary fair value allocation included contingent consideration in the amount of $4.4 million, which represented the estimated fair value of future payments to the former shareholders of Rave based on achieving revenue and gross margin percentage targets for the period ended April 30, 2020. The Company expects to complete the fair value allocation during the measurement period. The amortization period for all intangible assets acquired in connection with Rave is ten years . ​ In the nine months ended September 30, 2019, the Company completed various other acquisitions that collectively complemented the Company's existing product offerings or added aftermarket and software capabilities to the Company's existing businesses. ​ The following table reflects the consideration transferred and the respective reporting segment for each of these acquisitions: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Name of Acquisition Date Acquired Segment Consideration Cash Consideration Arxspan, LLC ​ March 4, 2019 BSI ​ $ 16.6 ​ $ 14.4 Ampegon PPT GmbH ​ March 7, 2019 BEST ​ 2.0 ​ 2.0 PMOD Technologies GmbH ​ July 1, 2019 ​ BSI ​ ​ 8.9 ​ ​ 7.9 ​ ​ ​ ​ ​ ​ $ 27.5 ​ $ 24.3 ​ 2018 ​ The following acquisitions occurred in the nine months ended September 30, 2018 (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ Company Acquired Anasys ​ JPK Reportable segment assigned BSI BSI Consideration Transferred: ​ ​ ​ ​ ​ ​ Cash paid ​ $ 27.0 ​ $ 16.6 Cash acquired ​ — ​ ​ (0.2) Contingent consideration ​ 5.3 ​ ​ 4.3 Total consideration transferred ​ $ 32.3 ​ $ 20.7 ​ ​ ​ ​ ​ ​ ​ Allocation of Consideration Transferred: ​ ​ ​ ​ Inventories ​ $ 2.8 ​ $ 3.0 Accounts receivable ​ ​ 0.8 ​ ​ 1.8 Other current and non-current assets ​ 1.1 ​ ​ 0.7 Intangible assets: ​ ​ ​ ​ Technology ​ 7.3 ​ ​ 7.0 Customer relationships ​ ​ 8.0 ​ ​ 7.5 Backlog ​ ​ 1.8 ​ ​ 1.1 Trade name ​ 0.6 ​ ​ 0.6 Goodwill ​ 16.6 ​ ​ 8.0 Deferred taxes, net ​ (3.2) ​ ​ (4.9) Liabilities assumed ​ (3.5) ​ ​ (4.1) Total consideration allocated ​ $ 32.3 ​ $ 20.7 ​ Anasys ​ On April 8, 2018, the Company acquired a 100 % interest in Anasys Instruments Corp. ("Anasys"), a privately held company, for a purchase price of $27.0 million with the potential for additional consideration of up to $9.6 million based on revenue achievements in 2019 and 2020. Anasys develops and manufactures nanoscale infrared spectroscopy and thermal measurement instruments. Anasys is located in Santa Barbara, California and was integrated into the Bruker Nano Group within the BSI reportable segment. ​ The preliminary fair value allocation included contingent consideration in the amount of $5.3 million, which represented the estimated fair value of future payments to the former shareholders of Anasys based on Anasys achieving annual revenue targets for the years 2019 and 2020. The Company completed the fair value allocation in the fourth quarter of 2018. The amortization period for all intangible assets acquired in connection with Anasys is eight years , except for backlog which will be amortized over one year . ​ JPK ​ On July 11, 2018, the Company acquired a 100% interest in JPK Instruments AG (“JPK”), a privately held company, for a purchase price of Euro 14.2 million (approximately $16.6 million), with the potential for additional consideration of up to Euro 4.3 million (approximately $5.0 million) based on various operational achievements throughout 2019 and 2020. JPK adds in-depth expertise in live-cell imaging, cellular mechanics, adhesion, and molecular force measurements, optical trapping, and biological stimulus-response characterization to Bruker’s capabilities. JPK is located in Berlin, Germany and was integrated into the Bruker Nano Group within the BSI reportable segment. ​ The preliminary fair value allocation included contingent consideration in the amount of $4.3 million, which represented the estimated fair value of future payments to the former shareholders of JPK based on JPK achieving various operational achievements for the years 2019 and 2020. The Company completed the fair value allocation in the second quarter of 2019. The amortization period for all intangible assets acquired in connection with JPK is eight years , except for backlog which will be amortized over one year .

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2019
Stock-Based Compensation
Stock-Based Compensation	4. Stock-Based Compensation ​ On May 14, 2010, the Bruker Corporation 2010 Incentive Compensation Plan (2010 Plan) was approved by the Company's stockholders. The 2010 Plan provided for the issuance of up to 8,000,000 shares of the Company's common stock. The 2010 Plan allowed a committee of the Board of Directors (Compensation Committee) to grant incentive stock options, non-qualified stock options and restricted stock awards. The Compensation Committee had the authority to determine which employees would receive the awards, the amount of the awards and other terms and conditions of any awards. Awards granted under the 2010 Plan typically were made subject to a vesting period of three to five years . ​ On May 20, 2016, the Bruker Corporation 2016 Incentive Compensation Plan (2016 Plan) was approved by the Company's stockholders. With the approval of the 2016 Plan, no further grants have been made under the 2010 Plan. The 2016 Plan provides for the issuance of up to 9,500,000 shares of the Company's common stock and permits the grant of awards of non-qualified stock options, incentive stock options, stock appreciation rights, restricted stock, unrestricted stock, restricted stock units, performance shares and performance units, as well as cash-based awards. The 2016 Plan is administered by the Compensation Committee. The Compensation Committee has the authority to determine which employees will receive awards, the amount of any awards, and other terms and conditions of such awards. Awards granted under the 2016 Plan typically vest over a period of one to four years . ​ The Company recorded stock-based compensation expense as follows in the unaudited condensed consolidated statements of income and comprehensive income (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2019 2018 2019 2018 Stock options ​ $ 0.7 ​ $ 1.2 ​ $ 2.1 ​ $ 3.2 Restricted stock awards ​ 0.1 ​ 0.3 ​ 0.3 ​ 0.7 Restricted stock units ​ ​ 2.7 ​ ​ 1.8 ​ ​ 6.3 ​ ​ 4.3 Total stock-based compensation ​ $ 3.5 ​ $ 3.3 ​ $ 8.7 ​ $ 8.2 ​ In addition to the awards above, the Company recorded stock-based compensation expense of $0.6 million and $1.4 million in the three and nine months ended September 30, 2019, respectively, related to the 2018 acquisition of Mestrelab Research, S.L. (Mestrelab). ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2019 2018 2019 2018 Costs of product revenue ​ $ 0.5 ​ $ 0.5 ​ $ 1.3 ​ $ 1.2 Selling, general and administrative ​ 2.5 ​ 2.3 ​ 6.1 ​ 5.8 Research and development ​ ​ 0.5 ​ ​ 0.5 ​ ​ 1.3 ​ ​ 1.2 Total stock-based compensation ​ $ 3.5 ​ $ 3.3 ​ $ 8.7 ​ $ 8.2 ​ Stock-based compensation expense is recognized on a straight-line basis over the underlying requisite service period of the stock-based award. ​ Stock options to purchase the Company's common stock are periodically awarded to executive officers and other employees of the Company subject to a vesting period of three to four years. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. Assumptions for the nine months ended September 30, 2019 and 2018 regarding volatility, expected life, dividend yield and risk-free interest rates are required for the Black-Scholes model and are presented in the table below: ​ ​ ​ ​ ​ ​ ​ ​ 2019 2018 Risk-free interest rates 1.55 % 2.80 % Expected life 5.33 years 5.38 years Volatility 29.57 % 28.46 % Expected dividend yield 0.38 % 0.47 % ​ Stock option activity for the nine months ended September 30, 2019 was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ ​ ​ ​ Weighted ​ Remaining ​ Aggregate ​ ​ Shares Subject ​ Average ​ Contractual ​ Intrinsic Value ​ to Options Option Price Term (Yrs) (in millions) (b) Outstanding at December 31, 2018 2,593,310 ​ $ 21.41 ​ ​ ​ ​ ​ Granted ​ 112,232 ​ ​ 44.17 ​ ​ ​ ​ ​ Exercised (465,701) ​ 19.27 ​ ​ ​ ​ ​ Forfeited/Expired (85,340) ​ 22.35 ​ ​ ​ ​ ​ Outstanding at September 30, 2019 2,154,501 ​ $ 23.03 5.1 ​ $ 45.2 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Exercisable at September 30, 2019 1,544,782 ​ $ 20.49 4.8 ​ $ 36.2 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Exercisable and expected to vest at September 30, 2019 (a) 2,103,772 ​ $ 22.87 5.1 ​ $ 44.4 (a) In addition to the options that are vested at September 30, 2019, the Company expects a portion of the unvested options to vest in the future. Options expected to vest in the future are determined by applying an estimated forfeiture rate to the options that are unvested as of September 30, 2019. (b) The aggregate intrinsic value is based on the positive difference between the fair value of the Company’s common stock price of $43.93 on September 30, 2019 and the exercise price of the underlying stock options. ​ The weighted average fair value of options granted was $11.16 and $9.50 per share during the nine months ended September 30, 2019 and 2018, respectively. ​ The total intrinsic value of options exercised was $10.3 million and $7.2 million for the nine months ended September 30, 2019 and 2018, respectively. ​ Restricted stock award activity for the nine months ended September 30, 2019 was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average Grant ​ ​ Shares Subject ​ Date Fair ​ to Restriction Value Outstanding at December 31, 2018 ​ 24,633 ​ $ 19.82 Vested (24,633) ​ 19.82 Outstanding at September 30, 2019 — ​ $ — ​ The total fair value of restricted stock awards vested was $1.0 million and $1.1 million in the nine months ended September 30, 2019 and 2018, respectively. ​ Restricted stock unit activity for the nine months ended September 30, 2019 was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average Grant ​ ​ Shares Subject ​ Date Fair ​ to Restriction Value Outstanding at December 31, 2018 806,249 ​ $ 29.88 Granted ​ 346,462 ​ ​ 40.66 Vested (213,286) ​ 31.14 Forfeited ​ (32,482) ​ ​ 29.20 Outstanding at September 30, 2019 906,943 ​ $ 33.73 ​ The total fair value of restricted stock units vested was $6.6 million and $3.7 million for the nine months ended September 30, 2019 and 2018, respectively. ​ At September 30, 2019, the Company expects to recognize pre-tax stock-based compensation expense of $3.3 million associated with outstanding stock option awards granted under the Company's stock plans over the weighted average remaining service period of 2.5 years. The Company does not expect to recognize any additional pre-tax stock-based compensation expense for restricted stock awards granted under the Company's stock plans. The Company also expects to recognize additional pre-tax stock-based compensation expense of $24.9 million associated with outstanding restricted stock units granted under the 2016 Plan over the weighted average remaining service period of 3.0 years.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2019
Earnings Per Share
Earnings Per Share	5. Earnings Per Share ​ Net income per common share attributable to Bruker Corporation shareholders is calculated by dividing net income attributable to Bruker Corporation, adjusted to reflect changes in the redemption value of the redeemable noncontrolling interest, by the weighted-average number of shares outstanding during the period. The diluted net income per share computation includes the effect of shares which would be issuable upon the exercise of outstanding stock options and the vesting of restricted stock, reduced by the number of shares which are assumed to be purchased by the Company under the treasury stock method. There was no redemption value adjustment of the redeemable noncontrolling interest for the three and nine months ended September 30, 2019 or 2018. ​ The following table sets forth the computation of basic and diluted weighted average shares outstanding and net income per common share attributable to Bruker shareholders (dollars in millions, except per share amounts): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2019 2018 2019 2018 Net income attributable to Bruker Corporation, as reported ​ $ 61.3 ​ $ 43.4 ​ $ 128.6 ​ $ 101.6 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average shares outstanding: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average shares outstanding-basic ​ 154.2 ​ 156.4 ​ 155.7 ​ 156.1 Effect of dilutive securities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Stock options and restricted stock awards and units ​ 1.4 ​ 1.0 ​ 1.3 ​ 1.1 ​ ​ 155.6 ​ 157.4 ​ 157.0 ​ 157.2 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net income per common share attributable to Bruker Corporation shareholders: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic ​ $ 0.40 ​ $ 0.28 ​ $ 0.83 ​ $ 0.65 Diluted ​ $ 0.39 ​ $ 0.28 ​ $ 0.82 ​ $ 0.65 ​ Stock options to purchase approximately 0.1 million shares and 0.6 million shares were excluded from the computation of diluted earnings per share in the three months ended September 30, 2019 and 2018, respectively, as their effect would have been anti-dilutive. Stock options to purchase approximately 0.5 million shares and 0.6 million shares were excluded from the computation of diluted earnings per share in the nine months ended September 30, 2019 and 2018, respectively, as their effect would have been anti-dilutive.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2019
Fair Value of Financial Instruments
Fair Value of Financial Instruments	6. Fair Value of Financial Instruments ​ The Company applies the following hierarchy to determine the fair value of financial instruments, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. The levels in the hierarchy are defined as follows: ​ ● Level 1: Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. ​ ● Level 2: Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. ​ ● Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement. ​ The valuation techniques that may be used by the Company to determine the fair value of Level 2 and Level 3 financial instruments are the market approach, the income approach and the cost approach. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value based on current market expectations about those future amounts, including present value techniques, option-pricing models and the excess earnings method. The cost approach is based on the amount that would be required to replace the service capacity of an asset (replacement cost). ​ The following tables set forth the Company's financial instruments that are measured at fair value on a recurring basis and presents them within the fair value hierarchy using the lowest level of input that is significant to the fair value measurement at September 30, 2019 and December 31, 2018 (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Quoted Prices Significant ​ ​ ​ ​ ​ ​ ​ ​ in Active ​ Other ​ Significant ​ ​ ​ ​ ​ Markets ​ Observable ​ Unobservable ​ ​ ​ ​ ​ Available ​ Inputs ​ Inputs September 30, 2019 Total (Level 1) (Level 2) (Level 3) Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Embedded derivatives in purchase and delivery contracts ​ $ 0.3 ​ $ — ​ $ 0.3 ​ $ — Foreign exchange contracts ​ ​ 0.3 ​ ​ — ​ ​ 0.3 ​ ​ — Total assets recorded at fair value ​ $ 0.6 ​ $ — ​ $ 0.6 ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Contingent consideration ​ $ 15.5 ​ $ — ​ $ — ​ $ 15.5 Hybrid instrument liability ​ ​ 14.3 ​ ​ — ​ ​ — ​ ​ 14.3 Foreign exchange contracts ​ ​ 1.5 ​ ​ — ​ ​ 1.5 ​ ​ — Embedded derivatives in purchase and delivery contracts ​ ​ 0.8 ​ ​ — ​ ​ 0.8 ​ ​ — Fixed price commodity contracts ​ ​ 0.2 ​ ​ — ​ ​ 0.2 ​ ​ — Total liabilities recorded at fair value ​ $ 32.3 ​ $ — ​ $ 2.5 ​ $ 29.8 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Quoted Prices Significant ​ ​ ​ ​ ​ ​ ​ ​ in Active ​ Other ​ Significant ​ ​ ​ ​ ​ Markets ​ Observable ​ Unobservable ​ ​ ​ ​ ​ Available ​ Inputs ​ Inputs December 31, 2018 Total (Level 1) (Level 2) (Level 3) Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Foreign exchange contracts ​ $ 0.2 ​ $ — ​ $ 0.2 ​ $ — Embedded derivatives in purchase and delivery contracts ​ ​ 0.4 ​ ​ — ​ ​ 0.4 ​ ​ — Total assets recorded at fair value ​ $ 0.6 ​ $ — ​ $ 0.6 ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Contingent consideration ​ $ 15.1 ​ $ — ​ $ — ​ $ 15.1 Hybrid instrument liability ​ ​ 12.9 ​ ​ — ​ ​ — ​ ​ 12.9 Foreign exchange contracts ​ ​ 2.8 ​ ​ — ​ ​ 2.8 ​ ​ — Embedded derivatives in purchase and delivery contracts ​ 0.9 ​ — ​ 0.9 ​ — Fixed price commodity contracts ​ ​ 0.5 ​ ​ — ​ ​ 0.5 ​ ​ — Total liabilities recorded at fair value ​ $ 32.2 ​ $ — ​ $ 4.2 ​ $ 28.0 ​ The Company's financial instruments consist primarily of restricted cash, derivative instruments consisting of foreign exchange contracts, commodity contracts, derivatives embedded in certain purchase and sale contracts, accounts receivable, borrowings under a revolving credit agreement, accounts payable, contingent consideration, a hybrid instrument liability and long-term debt. The carrying amounts of the Company's cash equivalents, short-term investments and restricted cash, accounts receivable, borrowings under a revolving credit agreement and accounts payable approximate fair value because of their short-term nature. Derivative assets and liabilities are measured at fair value on a recurring basis. The Company's long-term debt consists principally of a private placement arrangement entered into in 2012 with various fixed interest rates based on the maturity date. The fair value of the long-term fixed interest rate debt, which has been classified as Level 2, was $216.1 million and $228.8 million at September 30, 2019 and December 31, 2018, respectively, based on the outstanding amount at September 30, 2019 and December 31, 2018, market prices and observable sources with similar maturity dates. ​ The Company measures certain assets and liabilities at fair value with changes in fair value recognized in earnings. Fair value treatment may be elected either upon initial recognition of an eligible asset or liability or, for an existing asset or liability, if an event triggers a new basis of accounting. The Company did not elect to remeasure any of its existing financial assets or liabilities and did not elect the fair value option for any financial assets or liabilities which originated during the three or nine months ended September 30, 2019 or 2018. ​ As part of certain acquisitions, the Company recorded contingent consideration liabilities that have been classified as Level 3 in the fair value hierarchy. The contingent consideration represents the estimated fair value of future payments to the former shareholders of certain acquired companies based on the applicable acquired company achieving annual revenue and gross margin targets in certain years as specified in the relevant purchase and sale agreement. The Company initially values the contingent considerations by using a Monte Carlo simulation or an income approach method. The Monte Carlo method models future revenue and costs of goods sold projections and discounts the average results to present value. The income approach method involves calculating the earnout payment based on the forecasted cash flows, adjusting the future earnout payment for the risk of reaching the projected financials, and then discounting the future payments to present value by the counterparty risk. The counterparty risk considers the risk of the buyer having the cash to make the earnout payments and is commensurate with a cost of debt over an appropriate term. ​ The following table sets forth the changes in contingent consideration liabilities for the nine months ended September 30, 2019 (dollars in millions): ​ ​ ​ ​ ​ Balance at December 31, 2018 $ 15.1 Current period additions ​ 5.4 Current period adjustments ​ 1.4 Current period settlements ​ (6.1) Foreign currency effect ​ (0.3) Balance at September 30, 2019 ​ $ 15.5 ​ As part of the Mestrelab acquisition, the Company entered into an agreement with the noncontrolling interest holders that provides the Company with the right to purchase, and the noncontrolling interest holders with the right to sell, the remaining 49% of Mestrelab for cash at a contractually defined redemption value. These rights (an embedded derivative) are exercisable beginning in 2022 and can be accelerated, at a discounted redemption value, upon certain events related to post combination services. As the option is tied to continued employment, the Company classified the hybrid instrument (noncontrolling interest with an embedded derivative) as a long-term liability on the consolidated balance sheet. Subsequent to the acquisition, the carrying value of the hybrid instrument is remeasured to fair value with changes recorded to stock-based compensation expense in proportion to the requisite service period vested. The hybrid instrument is classified as Level 3 in the fair value hierarchy. ​ The following table sets forth the changes in hybrid instrument liability for the nine months ended September 30, 2019 (dollars in millions): ​ ​ ​ ​ ​ Balance at December 31, 2018 $ 12.9 Current period adjustments ​ ​ 1.4 Balance at September 30, 2019 ​ $ 14.3 ​

Restricted Cash

Restricted Cash	9 Months Ended
	Sep. 30, 2019
Restricted Cash
Restricted Cash	7. Restricted Cash ​ Restricted cash is included as a component of cash, cash equivalents, and restricted cash on the Company's unaudited condensed consolidated statement of cash flows. ​ The inclusion of restricted cash increased the balances of the unaudited condensed consolidated statement of cash flows as follows (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, ​ 2019 2018 Beginning Balance ​ $ 3.9 ​ $ 3.9 Ending Balance ​ 3.7 ​ 4.7 ​

Inventories

Inventories	9 Months Ended
	Sep. 30, 2019
Inventories
Inventories	8. Inventories ​ Inventories consisted of the following (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, December 31, ​ 2019 2018 Raw materials ​ $ 194.6 ​ $ 164.5 Work-in-process ​ 216.3 ​ 182.4 Finished goods ​ 101.8 ​ 94.8 Demonstration units ​ 74.0 ​ 67.9 Inventories ​ $ 586.7 ​ $ 509.6 ​ Finished goods include in-transit systems that have been shipped to the Company's customers, but not yet installed and accepted by the customer. As of September 30, 2019 and December 31, 2018, the value of inventory-in-transit was $27.8 million and $38.3 million, respectively.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets
Goodwill and Intangible Assets	9. Goodwill and Intangible Assets ​ The following table sets forth the changes in the carrying amount of goodwill for the three months ended September 30, 2019 (dollars in millions): ​ ​ ​ ​ ​ Balance at December 31, 2018 $ 275.7 Current period additions ​ ​ 13.9 Current period adjustments ​ ​ (0.6) Foreign currency effect ​ ​ (6.7) Balance at September 30, 2019 ​ $ 282.3 ​ The following is a summary of intangible assets, excluding goodwill (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2019 ​ December 31, 2018 ​ ​ Gross ​ ​ ​ ​ ​ ​ ​ Gross ​ ​ ​ ​ ​ ​ ​ ​ Carrying ​ Accumulated ​ Net Carrying ​ Carrying ​ Accumulated ​ Net Carrying ​ Amount Amortization Amount Amount Amortization Amount Existing technology and related patents ​ $ 294.4 ​ $ (175.0) ​ $ 119.4 ​ $ 272.6 ​ $ (160.5) ​ $ 112.1 Customer relationships ​ 131.1 ​ (27.1) ​ 104.0 ​ 112.0 ​ (18.1) ​ 93.9 Non compete contracts ​ 1.8 ​ (1.8) ​ — ​ ​ 1.8 ​ ​ (1.8) ​ ​ — Trade names ​ 13.2 ​ (2.5) ​ 10.7 ​ 11.6 ​ (1.6) ​ 10.0 Other ​ ​ 5.4 ​ ​ (5.2) ​ ​ 0.2 ​ ​ 5.1 ​ ​ (2.4) ​ ​ 2.7 Intangible assets ​ $ 445.9 ​ $ (211.6) ​ $ 234.3 ​ $ 403.1 ​ $ (184.4) ​ $ 218.7 ​ For the three months ended September 30, 2019 and 2018, the Company recorded amortization expense of $9.2 million and $6.9 million, respectively, related to intangible assets subject to amortization. For the nine months ended September 30, 2019 and 2018, the Company recorded amortization expense of $29.2 million and $21.5 million, respectively, related to intangible assets subject to amortization.

Debt

Debt	9 Months Ended
	Sep. 30, 2019
Debt
Debt	10. Debt ​ The Company’s debt obligations as of September 30, 2019 and December 31, 2018 consisted of the following (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, December 31, ​ 2019 2018 US Dollar revolving loan under the 2015 Credit Agreement ​ $ 310.4 ​ $ 111.6 US Dollar notes under the Note Purchase Agreement ​ 205.0 ​ 220.0 Unamortized debt issuance costs under the Note Purchase Agreement ​ ​ (0.4) ​ ​ (0.5) Other revolving loans ​ ​ — ​ ​ 2.9 Capital lease obligations and other loans ​ 3.8 ​ 7.1 Total debt ​ 518.8 ​ 341.1 Current portion of long-term debt ​ (0.3) ​ (18.5) Total long-term debt, less current portion ​ $ 518.5 ​ $ 322.6 ​ On October 27, 2015, the Company entered into a new revolving credit agreement, referred to as the 2015 Credit Agreement. The 2015 Credit Agreement provides a maximum commitment on the Company’s revolving credit line of $500 million and a maturity date of October 2020. Borrowings under the revolving credit line of the 2015 Credit Agreement accrue interest, at the Company’s option, at either (a) the greatest of (i) the prime rate , (ii) the federal funds rate plus 0.50% and (iii) adjusted LIBOR plus 1.00%, plus margins ranging from 0.00% to 0.30% or (b) LIBOR , plus margins ranging from 0.90% to 1.30 %. There is also a facility fee ranging from 0.10% to 0.20%. ​ Borrowings under the 2015 Credit Agreement are secured by guarantees from certain material subsidiaries, as defined in the 2015 Credit Agreement. The 2015 Credit Agreement also requires the Company to maintain certain financial ratios related to maximum leverage and minimum interest coverage (as defined in the 2015 Credit Agreement). Specifically, the Company’s leverage ratio cannot exceed 3.5 and the Company’s interest coverage ratio cannot be less than 2.5 . In addition to the financial ratios, the 2015 Credit Agreement contains negative covenants, including among others, restrictions on liens, indebtedness of the Company and its subsidiaries, asset sales, dividends and transactions with affiliates. Failure to comply with any of these restrictions or covenants may result in an event of default on the 2015 Credit Agreement, which could permit acceleration of the debt and require the Company to prepay the debt before its scheduled due date. ​ The following is a summary of the maximum commitments and the net amounts available to the Company under the 2015 Credit Agreement and other lines of credit with various financial institutions located primarily in Germany and Switzerland that are unsecured and typically due upon demand with interest payable monthly, at September 30, 2019 (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Total Amount ​ ​ Outstanding ​ ​ ​ ​ Average ​ Committed by ​ Outstanding ​ Letters of ​ Total Amount ​ Interest Rate Lenders Borrowings Credit Available 2015 Credit Agreement 2.5 % $ 500.0 ​ $ 310.4 ​ $ 1.1 ​ $ 188.5 Alicona revolving line of credit ​ — ​ ​ 5.3 ​ ​ — ​ ​ — ​ ​ 5.3 Other lines of credit — ​ 231.4 ​ — ​ 126.4 ​ 105.0 Total revolving lines of credit ​ ​ ​ $ 736.7 ​ $ 310.4 ​ $ 127.5 ​ $ 298.8 ​ In January 2012, the Company entered into a note purchase agreement, referred to as the Note Purchase Agreement, with a group of accredited institutional investors. Pursuant to the Note Purchase Agreement, the Company issued and sold $240.0 million of senior notes, referred to as the Senior Notes, which consisted of the following: ​ ● $20.0 million 3.16% Series 2012A Senior Notes, Tranche A, due January 18, 2017; ​ ● $15.0 million 3.74% Series 2012A Senior Notes, Tranche B, due January 18, 2019; ​ ● $105.0 million 4.31% Series 2012A Senior Notes, Tranche C, due January 18, 2022; and ​ ● $100.0 million 4.46% Series 2012A Senior Notes, Tranche D, due January 18, 2024. ​ On January 18, 2017, the outstanding $20.0 million principal amount of Tranche A of the Senior Notes was repaid in accordance with the terms of the Note Purchase Agreement. On January 18, 2019, the outstanding $15.0 million principal amount of Tranche B of the Senior Notes was repaid in accordance with the terms of the Note Purchase Agreement. ​ Under the terms of the Note Purchase Agreement, the Company may issue and sell additional senior notes up to an aggregate principal amount of $600 million, subject to certain conditions. Interest on the Senior Notes is payable semi-annually on January 18 and July 18 of each year. The Senior Notes are unsecured obligations of the Company and are fully and unconditionally guaranteed by certain of the Company’s direct and indirect subsidiaries. The Senior Notes rank pari passu in right of repayment with the Company’s other senior unsecured indebtedness. The Company may prepay some or all of the Senior Notes at any time in an amount not less than 10% of the original aggregate principal amount of the Senior Notes to be prepaid, at a price equal to the sum of (a) 100% of the principal amount thereof, plus accrued and unpaid interest, and (b) the applicable make-whole amount, upon not less than 30 and no more than 60 days written notice to the holders of the Senior Notes. In the event of a change in control of the Company, as defined in the Note Purchase Agreement, the Company may be required to prepay the Notes at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest. ​ The Note Purchase Agreement contains affirmative covenants, including, without limitation, maintenance of corporate existence, compliance with laws, maintenance of insurance and properties, payment of taxes, addition of subsidiary guarantors and furnishing notices and other information. The Note Purchase Agreement also contains certain restrictive covenants that restrict the Company’s ability to, among other things, incur liens, transfer or sell assets, engage in certain mergers and consolidations and enter into transactions with affiliates. The Note Purchase Agreement also includes customary representations and warranties and events of default. In the case of an event of default arising from specified events of bankruptcy or insolvency, all outstanding Senior Notes will become due and payable immediately without further action or notice. In the case of a payment event of default, any holder of Senior Notes affected thereby may declare all Senior Notes held by it due and payable immediately. In the case of any other event of default, a majority of the holders of the Senior Notes may declare all the Senior Notes to be due and payable immediately. Pursuant to the Note Purchase Agreement, so long as any Senior Notes are outstanding the Company will not permit (i) its leverage ratio, as determined pursuant to the Note Purchase Agreement, to exceed 3.50 to 1.00 as of the end of any fiscal quarter, (ii) its interest coverage ratio, as determined pursuant to the Note Purchase Agreement, to be less than 2.50 to 1 as of the end of any fiscal quarter for any period of four consecutive fiscal quarters or (iii) priority debt at any time to exceed 25% of consolidated net worth, as determined pursuant to the Note Purchase Agreement. ​ As of September 30, 2019, the Company was in compliance with the covenants of the Note Purchase Agreement and the 2015 Credit Agreement.

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	9 Months Ended
	Sep. 30, 2019
Derivative Instruments and Hedging Activities
Derivative Instruments and Hedging Activities	11. Derivative Instruments and Hedging Activities ​ Interest Rate Risks ​ The Company’s exposure to interest rate risk relates primarily to outstanding variable rate debt and adverse movements in the related short-term market rates. Typically, the most significant component of the Company’s interest rate risk relates to amounts outstanding under the 2015 Credit Agreement. ​ Foreign Exchange Rate Risk Management ​ The Company generates a substantial portion of its revenues and expenses in international markets which subjects its operations to the exposure of exchange rate fluctuations. The impact of currency exchange rate movement can be positive or negative in any period. The Company periodically enters into foreign currency contracts in order to minimize the volatility that fluctuations in currency translation have on its monetary transactions. Under these arrangements, the Company typically agrees to purchase a fixed amount of a foreign currency in exchange for a fixed amount of U.S. Dollars or other currencies on specified dates with maturities of less than twelve months, with some agreements extending to longer periods. The Company had the following notional amounts outstanding under foreign exchange contracts at September 30, 2019 and December 31, 2018 (in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Notional ​ ​ ​ ​ ​ Notional ​ ​ ​ ​ ​ ​ ​ ​ Amount in Buy ​ ​ ​ ​ ​ Amount in U.S. ​ Fair Value of ​ Fair Value of Buy Currency Sell Maturity Dollars Assets Liabilities September 30, 2019: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Euro ​ 17.9 ​ U.S. Dollars ​ October 2019 ​ $ 20.1 ​ $ — ​ $ 0.6 Great Britain Pound ​ 8.1 ​ Euro ​ October 2019 ​ ​ 9.7 ​ ​ 0.3 ​ ​ — Swiss Francs ​ 9.4 ​ Japanese Yen ​ October 2019 ​ ​ 9.6 ​ ​ — ​ ​ 0.1 Swiss Francs ​ 7.7 ​ U.S. Dollars ​ October 2019 ​ ​ 7.9 ​ ​ — ​ ​ 0.2 Euro ​ 6.5 ​ Great Britain Pound ​ October 2019 to October 2020 ​ ​ 7.2 ​ ​ — ​ ​ 0.1 Taiwan Dollar ​ 204.0 ​ U.S. Dollars ​ October 2019 ​ ​ 6.6 ​ ​ — ​ ​ 0.1 Chinese Renminbi ​ 72.3 ​ U.S. Dollars ​ October 2019 ​ ​ 10.5 ​ ​ — ​ ​ 0.4 Euro ​ 2.9 ​ Chinese Renminbo ​ October 2019 ​ ​ 3.1 ​ ​ — ​ ​ — Singapore Dollar ​ 4.2 ​ U.S. Dollars ​ October 2019 ​ ​ 3.1 ​ ​ — ​ ​ — Singapore Dollar ​ 2.8 ​ Euro ​ October 2019 ​ ​ 2.0 ​ ​ — ​ ​ — Swedish Krona ​ 26.7 ​ Euro ​ October 2019 ​ ​ 2.7 ​ ​ — ​ ​ — ​ ​ ​ ​ ​ ​ ​ ​ $ 82.5 ​ $ 0.3 ​ $ 1.5 December 31, 2018: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Euro ​ 25.4 ​ U.S. Dollars ​ January 2019 ​ $ 31.1 ​ $ — ​ $ 2.1 U.S. Dollars ​ 8.5 Euro January 2019 ​ 8.6 ​ — ​ 0.1 Swiss Francs ​ 11.1 ​ U.S. Dollars ​ January 2019 ​ ​ 11.3 ​ ​ — ​ ​ — U.S. Dollars ​ 2.1 ​ Swiss Francs ​ January 2019 ​ ​ 2.1 ​ ​ — ​ ​ — Swiss Francs ​ 10.4 ​ Japanese Yen ​ April 2019 ​ ​ 10.8 ​ ​ — ​ ​ 0.2 U.S. Dollars ​ 1.5 ​ Canadian Dollars ​ January 2019 ​ ​ 1.5 ​ ​ — ​ ​ — Singapore Dollar ​ 4.3 ​ U.S. Dollars ​ January 2019 ​ ​ 3.1 ​ ​ — ​ ​ — Chinese Renminbi ​ 41.1 ​ U.S. Dollars ​ January 2019 ​ ​ 5.9 ​ ​ 0.1 ​ ​ — Great Britian Pound ​ 15.4 ​ Euro ​ January 2019 ​ ​ 20.0 ​ ​ — ​ ​ 0.4 Euro ​ 6.9 ​ Great Britian Pound ​ May 2019 to October 2020 ​ ​ 8.0 ​ ​ 0.1 ​ ​ — ​ ​ ​ ​ ​ ​ ​ ​ $ 102.4 ​ $ 0.2 ​ $ 2.8 ​ In addition, the Company periodically enters into purchase and sales contracts denominated in currencies other than the functional currency of the parties to the transaction. The Company accounts for these transactions separately valuing the “embedded derivative” component of these contracts. The contracts, denominated in currencies other than the functional currency of the transacting parties, amounted to $81.3 million for the delivery of products and $7.6 million for the purchase of products at September 30, 2019 and $113.5 million for the delivery of products and $6.0 million for the purchase of products at December 31, 2018. The changes in the fair value of these embedded derivatives are recorded in interest and other income (expense), net in the consolidated statements of income and comprehensive income (loss). ​ Commodity Price Risk Management ​ The Company has arrangements with certain customers under which it has a firm commitment to deliver copper based superconductor wire at a fixed price. In order to minimize the volatility that fluctuations in the price of copper have on the Company’s sales of these commodities, the Company enters into commodity hedge contracts. At September 30, 2019 and December 31, 2018, the Company had fixed price commodity contracts with notional amounts aggregating $5.1 million and $6.8 million, respectively. The changes in the fair value of these commodity contracts are recorded within interest and other income (expense), net in the unaudited condensed consolidated statements of income and comprehensive income (loss). ​ The fair value of the derivative instruments described above is recorded in the unaudited condensed consolidated balance sheets for the periods as follows (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, December 31, ​ Balance Sheet Location 2019 2018 Derivative assets: ​ ​ ​ ​ ​ ​ ​ ​ Foreign exchange contracts Other current assets ​ $ 0.3 ​ $ 0.2 Embedded derivatives in purchase and delivery contracts ​ Other current assets ​ ​ 0.2 ​ ​ 0.2 Embedded derivatives in purchase and delivery contracts ​ Other long-term assets ​ ​ 0.1 ​ ​ 0.2 ​ ​ ​ ​ ​ ​ ​ ​ ​ Derivative liabilities: ​ ​ ​ ​ ​ ​ ​ ​ Foreign exchange contracts ​ Other current liabilities ​ $ 1.5 ​ $ 2.8 Embedded derivatives in purchase and delivery contracts ​ Other current liabilities ​ ​ 0.8 ​ ​ 0.9 Fixed price commodity contracts ​ Other current liabilities ​ ​ 0.2 ​ ​ 0.5 ​ The impact on net income of unrealized gains and losses resulting from changes in the fair value of derivative instruments not designated as hedging instruments are as follows (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2019 2018 2019 2018 Foreign exchange contracts ​ $ (1.0) ​ $ 1.4 ​ $ 1.3 ​ $ (6.7) Embedded derivatives in purchase and delivery contracts ​ (0.1) ​ — ​ — ​ 1.3 Fixed price commodity contracts ​ — ​ (0.3) ​ 0.3 ​ (1.2) Net impact to interest and other income (expense) ​ $ (1.1) ​ $ 1.1 ​ $ 1.6 ​ $ (6.6) ​ The amounts related to derivative instruments not designated as hedging instruments are recorded within interest and other income (expense), net in the unaudited condensed consolidated statements of income and comprehensive income (loss).

Provision for Income Taxes

Provision for Income Taxes	9 Months Ended
	Sep. 30, 2019
Provision for Income Taxes
Provision for Income Taxes	12. Provision for Income Taxes ​ The Company accounts for income taxes using the asset and liability approach by recognizing deferred tax assets and liabilities for the expected future tax consequences of differences between the financial statement basis and the tax basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differences are expected to be reflected in the tax return. The Company records a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized. In addition, the Company accounts for uncertain tax positions that have reached a minimum recognition threshold. ​ The income tax provision for the three months ended September 30, 2019 and 2018 was $21.7 million and $21.2 million, respectively, representing effective tax rates of 26.1% and 32.4 %, respectively. The income tax provision for the nine months ended September 30, 2019 and 2018 was $40.0 million and $41.4 million, respectively, representing effective tax rates of 23.6% and 28.7%, respectively. The Company's effective tax rate may change over time as the amount or mix of income and taxes changes among the jurisdictions in which the Company is subject to tax. ​ As of September 30, 2019 and December 31, 2018, the Company had unrecognized tax benefits, excluding penalties and interest, of approximately $6.5 million which, if recognized, would result in a reduction of the Company’s effective tax rate. The Company recognizes penalties and interest related to unrecognized tax benefits in the provision for income taxes. As of September 30, 2019 and December 31, 2018, approximately $0.3 million and $0.2 million, respectively, of accrued interest and penalties related to uncertain tax positions was included in other long-term liabilities on the Company’s unaudited condensed consolidated balance sheets. Penalties and interest of $0.1 million were recorded in the provision for income taxes for unrecognized tax benefits during the three and nine months ended September 30, 2019. There were no penalties or interest recorded in the three and nine months ended September 30, 2018. ​ The Company files tax returns in the United States, which includes federal, state and local jurisdictions, and many foreign jurisdictions with varying statutes of limitations. The Company considers Germany, the United States and Switzerland to be its significant tax jurisdictions. The majority of the Company’s earnings are derived in Germany and Switzerland. Accounting for the various federal and local taxing authorities, the statutory rates for 2019 are approximately 30.0% and 20.0% for Germany and Switzerland, respectively. The mix of earnings in those two jurisdictions resulted in an increase of 5.3% from the U.S. statutory rate of 21.0% in the nine months ended September 30, 2019. The Company has not been a party to any material tax holiday agreements. The tax years 2013 to 2018 are open to examination in Germany and Switzerland. Tax years 2011 to 2018 remain open for examination in the United States. ​

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies
Commitments and Contingencies	13. Commitments and Contingencies ​ In accordance with ASC Topic 450, Contingencies, the Company accrues anticipated costs of settlement, damages or other costs to the extent specific losses are probable and estimable. ​ Letters of Credit and Guarantees ​ At September 30, 2019 and December 31, 2018, the Company had bank guarantees of $127.5 million and $138.3 million, respectively, related primarily to customer advances. These arrangements guarantee the refund of advance payments received from customers in the event that the merchandise is not delivered or warranty obligations are not fulfilled in compliance with the terms of the contract. ​ Litigation and Related Contingencies ​ Lawsuits, claims and proceedings of a nature considered normal to its businesses may be pending from time to time against the Company. Third parties might allege that the Company or its collaborators are infringing their patent rights or that the Company is otherwise violating their intellectual property rights. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management's best estimate of probable loss. Disclosure is also provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. The Company believes the outcome of pending proceedings, individually and in the aggregate, will not have a material impact on the Company's financial statements. ​ On September 25, 2019, in a complaint filed in the Düsseldorf, Germany, District Court, Carl Zeiss Microscopy GmbH, a subsidiary of Carl Zeiss AG (Zeiss), sued Luxendo GmbH (Luxendo), a subsidiary of Bruker Corporation, for infringement of a recently registered German utility model Gebrauchsmuster licensed to Zeiss pertaining to one specific Luxendo product category. The Company intends to vigorously defend against this claim. ​ On September 23, 2019, in a complaint filed in the Düsseldorf, Germany, District Court, Micromass UK Limited, a subsidiary of Waters Corporation, sued Bruker Corporation, as well as its affiliate, Bruker Daltonik GmbH, for infringement of a European patent pertaining to our timsTOF product line. The Company intends to vigorously defend against this claim. ​ As of September 30, 2019 and December 31, 2018, no material accruals have been recorded for potential contingencies. ​ Governmental Investigations ​ The Company is subject to regulation by national, state and local government agencies in the United States and other countries in which it operates. From time to time, the Company is the subject of governmental investigations often involving regulatory, marketing and other business practices. These governmental investigations may result in the commencement of civil and criminal proceedings, fines, penalties and administrative remedies which could have a material adverse effect on the Company’s financial position, results of operations and/or liquidity. ​ In August 2018, the Korea Fair Trade Commission (KFTC) informed the Company that it was conducting an investigation into the public tender bidding activities of a number of life science instrument companies operating in Korea, including Bruker Korea Co., Ltd (Bruker Korea). The Company cooperated fully with the KFTC and on June 16, 2019, the KFTC announced its decision to impose a fine of approximately $20,000 on Bruker Korea and declined to impose any criminal liability against Bruker Korea in connection with this matter. ​ On October 19, 2017, the Company received a notice of investigation and subpoena to produce documents from the Division of Enforcement of the SEC. The subpoena sought information related to an employee terminated as part of a restructuring and certain matters involving the Company’s policies and accounting practices related to revenue recognition and restructuring activities, as well as related financial reporting, disclosure and compliance matters, since January 1, 2013. The subpoena also sought information concerning, among other things, the Company’s previously identified material weakness in internal controls over the accounting for income taxes, related financial reporting matters and certain payments for non-employee travel expenses. On April 25, 2019, the Staff notified the Company that it had concluded its investigation and, based on the information received to date, does not intend to recommend an enforcement action by the SEC against the Company. ​ Additionally, the Audit Committee of the Company’s Board of Directors, with the assistance of outside counsel, conducted an internal investigation into practices of certain business partners in China and into the conduct of former employees of the Bruker Optics division in China which raised questions of compliance with laws, including the U.S. Foreign Corrupt Practices Act, and/or compliance with the Company’s business policies and code of conduct. The Audit Committee has concluded its internal investigation. ​ As of September 30, 2019 and December 31, 2018, no material accruals have been recorded for potential contingencies related to these matters.

Leases

Leases	9 Months Ended
	Sep. 30, 2019
Leases
Leases	14. Leases ​ In February 2016, the FASB issued ASU No. 2016-02, Leases, which provides guidance on the recognition, measurement, presentation and disclosure of leases. The new standard, effective as of January 1, 2019, supersedes present U.S. GAAP guidance on leases and requires all leases with terms longer than 12 months to be reported on the balance sheet as right-of-use (ROU) assets and lease liabilities, as well as provide additional disclosures. The lease liability represents the lessee’s obligation to make lease payments arising from a lease and will be measured as the present value of the lease payments. The right-of-use asset represents the lessee’s right to use a specified asset for the lease term, and will be measured at the lease liability amount, adjusted for lease prepayment, lease incentives received and the lessee’s initial direct costs. ​ Under ASU No. 2016-02, companies are required to transition to the new standard in the period of adoption at the beginning of the earliest period presented in the financial statements (January 1, 2017 for the Company). In July 2018, the FASB issued ASU No. 2018-11 as an update to ASU No. 2016-02, which in part provided companies the option of transitioning to the new standard as of the adoption date and recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company adopted the new standard as of January 1, 2019 using the alternative transition method under ASU No. 2018-11 and recognized a cumulative-effect adjustment to the opening balance sheet. The Company's prior period financial statements were not adjusted due to adopting the new standard based on the alternative transition method. The Company elected the available package of practical expedients for leases that commenced prior to the effective date that allows it to not reassess: 1) whether any expired or existing contracts are or contain leases; 2) the lease classification for any expired or existing leases; and 3) the accounting treatment of initial direct costs for any expired or existing leases. The Company also elected the practical expedient that allows lessees to treat lease and non-lease components of leases as a single lease component for all asset classes. The adoption of the new standard resulted in recording $75.5 million and $77.9 million of ROU assets and lease liabilities, respectively, as of January 1, 2019 on the Company’s unaudited condensed consolidated balance sheet. The adoption of the new standard did not significantly affect the Company’s results of operations. ​ Starting in the first quarter of 2019, the Company accounts for leases in accordance with ASC 842, Leases. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Leases with a term greater than 12 months are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with an initial term of 12 months or less. Leases with an initial term of 12 months or less are directly expensed as incurred. Leases are classified as either operating or finance depending on the specific terms of the arrangement. ​ The Company’s leases mainly consist of facilities, office equipment, and vehicles. The majority of leases are classified as operating, with certain leases classified as finance leases based on the specific terms of the arrangement. The remaining lease term ranges from 2019 to 2029, with some leases including an option to extend the lease for varying periods of time or to terminate prior to the end of the lease term. Certain lease agreements contain provisions for future rent increases. Lease payments included in the measurement of the lease liability comprise fixed payments, and the exercise price of a Company option to purchase the underlying asset if the Company is reasonably certain to exercise the option. The Company’s leases typically do not contain residual value guarantees. ​ At the commencement date, operating and finance lease liabilities, and their corresponding ROU assets, are recorded based on the present value of lease payments over the expected lease term. The lease term includes the noncancellable period of the lease, plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. The interest rate implicit in lease contracts is typically not readily determinable, therefore an incremental borrowing rate is used to calculate the lease liability. The incremental borrowing rate is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the ROU asset may be required for items such as prepayments, lease incentives received or initial direct costs paid. ​ Operating lease cost is recognized over the lease term on a straight-line basis, while finance lease cost is amortized over the expected term on a straight-line basis. Variable lease cost not dependent on an index or rate is recognized when incurred. ​ The components of lease cost for the three and nine months ended September 30, 2019 are as follows (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended Nine Months Ended ​ ​ September 30, 2019 ​ September 30, 2019 Amortization of right-of-use assets ​ $ 0.1 ​ $ 0.2 Interest on lease liabilities ​ — ​ — Total finance lease cost ​ $ 0.1 ​ $ 0.2 ​ ​ ​ ​ ​ ​ ​ Operating lease cost ​ $ 6.1 ​ $ 18.8 Short term lease cost ​ 0.5 ​ 1.6 Variable lease cost ​ 1.0 ​ 2.7 Sublease income ​ (0.3) ​ (0.9) Total lease cost ​ $ 7.4 ​ $ 22.4 ​ Supplemental balance sheet information as of September 30, 2019 related to leases was as follows (dollars in millions): ​ ​ ​ ​ ​ ​ ​ September 30, 2019 Operating leases ​ ​ ​ ​ Operating lease assets, net ​ $ 68.9 ​ Other current liabilities ​ 20.4 ​ Operating lease liability - long term ​ 50.7 ​ ​ ​ ​ ​ ​ Finance leases ​ ​ ​ ​ Property, plant and equipment, net ​ $ 1.5 ​ Current portion of long-term debt ​ 0.4 ​ Long-term debt ​ 1.0 ​ ​ ​ ​ ​ ​ Weighted average remaining lease term ​ ​ ​ ​ Operating leases ​ 5.2 years Finance leases ​ 3.5 years ​ ​ ​ ​ ​ Weighted average discount rate ​ ​ ​ ​ Operating leases ​ 2.5 % Finance leases ​ 2.8 % ​ Supplemental cash flow information related to leases for the nine months ended September 30, 2019 was as follows (dollars in millions): ​ ​ ​ ​ ​ ​ Nine Months Ended ​ ​ September 30, 2019 ​ ​ ​ ​ Cash paid for amounts included in the measurement of lease liabilities ​ ​ ​ Operating cash flows from finance leases ​ $ — Operating cash flows from operating leases ​ 17.7 Financing cash flows from finance leases ​ 0.2 ​ ​ ​ ​ Right-of-use assets obtained in exchange for lease liabilities ​ ​ ​ Operating leases ​ $ 16.4 Finance leases ​ 0.8 ​ Future minimum lease payments under non-cancellable leases as of September 30, 2019 are as follows (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Leases Finance Leases 2019 (excluding the nine months ended September 30, 2019) ​ $ 5.9 ​ $ 0.1 2020 ​ 20.6 ​ 0.5 2021 ​ 15.2 ​ 0.4 2022 ​ 9.7 ​ 0.3 2023 ​ 7.6 ​ 0.2 Thereafter ​ 16.7 ​ — Total undiscounted lease payments ​ 75.7 ​ 1.5 Less: Imputed interest ​ (4.6) ​ (0.1) Total lease liabilities ​ $ 71.1 ​ $ 1.4 ​ As of December 31, 2018, minimum commitments for the Company’s leases as required under prior lease guidance in ASC 840 were as follows (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Leases Finance Leases 2019 ​ $ 25.3 ​ $ — 2020 ​ 19.1 ​ 0.1 2021 ​ 13.7 ​ 0.1 2022 ​ 9.3 ​ — 2023 ​ 7.3 ​ — Thereafter ​ 18.4 ​ — Total ​ $ 93.1 ​ $ 0.2 ​

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2019
Shareholders' Equity
Shareholders' Equity	15. Shareholders’ Equity ​ Share Repurchase Program ​ In May 2019, the Company’s Board of Directors approved a stock repurchase plan (the Repurchase Program) authorizing repurchases of common stock in the amount of up to $300.0 million from time to time, in amounts, at prices, and at such times as management deems appropriate, subject to market conditions, legal requirements and other considerations. The Company repurchased a total of 1,022,469 shares at an aggregate cost of $42.3 million in the three months ended September 30, 2019 and a total of 3,323,104 shares at an aggregate cost of $142.3 million in the nine months ended September 30, 2019. No repurchases occurred in the three and nine months ended September 30, 2018. Any future repurchases will be funded from cash on hand, future cash flows from operations and available borrowings under the revolving credit facility. The remaining authorization as of October 30, 2019 is $157.7 million and this Repurchase Program expires on May 13, 2021. ​ Cash Dividends on Shares of Common Stock ​ On February 22, 2016, the Company announced the establishment of a dividend policy and the declaration by its Board of Directors of an initial quarterly cash dividend in the amount of $0.04 per share of the Company's issued and outstanding common stock. Under the dividend policy, the Company will target a cash dividend to the Company's shareholders in the amount of $0.16 per share per annum, payable in equal quarterly installments. ​ Subsequent dividend declarations and the establishment of record and payment dates for such future dividend payments, if any, are subject to the Board of Directors' continuing determination that the dividend policy is in the best interests of the Company's shareholders. The dividend policy may be suspended or cancelled at the discretion of the Board of Directors at any time. ​ Accumulated Other Comprehensive Income (Loss) ​ Comprehensive income refers to revenues, expenses, gains and losses that under U.S. GAAP are included in other comprehensive income (loss), but excluded from net income as these amounts are recorded directly as an adjustment to shareholders’ equity, net of tax. The Company’s other comprehensive income (loss) is composed primarily of foreign currency translation adjustments and changes in the funded status of defined benefit pension plans. The following is a summary of comprehensive income (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2019 2018 2019 2018 Consolidated net income ​ $ 61.5 ​ $ 44.2 ​ $ 129.2 ​ $ 103.1 Foreign currency translation adjustments ​ (36.5) ​ (2.5) ​ (38.9) ​ (17.1) Pension liability adjustments, net of tax ​ 1.1 ​ 0.2 ​ 1.7 ​ 2.3 Net comprehensive income (loss) ​ 26.1 ​ 41.9 ​ 92.0 ​ 88.3 Less: Comprehensive income (loss) attributable to noncontrolling interests ​ 0.2 ​ 0.5 ​ 1.0 ​ 0.9 Less: Comprehensive income (loss) attributable to redeemable noncontrolling interest ​ ​ (1.2) ​ ​ — ​ ​ (1.8) ​ ​ — Comprehensive income (loss) attributable to Bruker Corporation ​ $ 27.1 ​ $ 41.4 ​ $ 92.8 ​ $ 87.4 ​ The following is a summary of the components of accumulated other comprehensive income, net of tax, at September 30, 2019 (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accumulated ​ ​ Foreign ​ Pension ​ Other ​ ​ Currency ​ Liability ​ Comprehensive ​ Translation Adjustment Income Balance at December 31, 2018 ​ $ 46.9 ​ $ (29.9) ​ $ 17.0 Other comprehensive income (loss) before reclassifications ​ ​ (37.6) ​ ​ 0.6 ​ ​ (37.0) Amounts reclassified from other comprehensive income (loss), net of tax of $0.2 million ​ ​ — ​ ​ 1.2 ​ ​ 1.2 Net current period other comprehensive income (loss) ​ ​ (37.6) ​ ​ 1.8 ​ ​ (35.8) Balance at September 30, 2019 ​ $ 9.3 ​ $ (28.1) ​ $ (18.8) ​

Other Charges (Gain), Net

Other Charges (Gain), Net	9 Months Ended
	Sep. 30, 2019
Other Charges (Gain), Net
Other Charges (Gain), Net	16. Other Charges (Gain), Net ​ The components of other charges (gain), net were as follows (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2019 2018 2019 2018 Information technology transformation costs ​ $ 0.8 ​ $ 1.1 ​ $ 2.8 ​ $ 3.5 Restructuring charges ​ (7.4) ​ 2.0 ​ (5.5) ​ 5.9 Acquisition-related charges ​ ​ 0.9 ​ ​ 1.2 ​ ​ 5.9 ​ ​ 2.3 Other ​ 0.4 ​ 0.9 ​ 1.7 ​ 3.5 Other charges (gain), net ​ $ (5.3) ​ $ 5.2 ​ $ 4.9 ​ $ 15.2 ​ Restructuring Initiatives ​ Restructuring charges for the three and nine month periods ended September 30, 2019 and 2018 include charges for various programs that were recorded in the accompanying unaudited condensed consolidated statements of income and comprehensive income. The following table sets forth the restructuring charges for the three and nine months ended September 30, 2019 and 2018 (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2019 2018 2019 2018 Cost of revenues $ 0.6 $ 0.5 ​ $ 4.1 $ 0.8 Other charges, net ​ (7.4) ​ 2.0 ​ ​ (5.5) ​ 5.9 ​ ​ $ (6.8) ​ $ 2.5 ​ $ (1.4) ​ $ 6.7 ​ In the three and nine months ended September 30, 2019, the restructuring charges included a gain of 7.8 million related to the sale of a building in Leipzig, Germany. ​ The following table sets forth the changes in restructuring reserves for the nine months ended September 30, 2019 (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Provisions ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ for Excess ​ Total Severance Exit Costs Inventory Balance at December 31, 2018 ​ $ 7.3 ​ $ 2.0 ​ $ 1.4 ​ $ 3.9 Restructuring charges ​ (1.4) ​ 4.1 ​ (5.9) ​ 0.4 Cash payments ​ (5.3) ​ (4.1) ​ (1.2) ​ — Other, non-cash adjustments and foreign currency effect ​ ​ 4.1 ​ ​ (0.5) ​ ​ 5.9 ​ ​ (1.3) Balance at September 30, 2019 ​ $ 4.7 ​ $ 1.5 ​ $ 0.2 ​ $ 3.0 ​

Interest and Other Income (Expe

Interest and Other Income (Expense), Net	9 Months Ended
	Sep. 30, 2019
Interest and Other Income (Expense), Net
Interest and Other Income (Expense), Net	17. Interest and Other Income (Expense), Net ​ The components of interest and other income (expense), net, were as follows (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2019 2018 2019 2018 Interest expense, net ​ $ (4.7) ​ $ (2.3) ​ $ (11.5) ​ $ (8.3) Exchange (losses) gains on foreign currency transactions ​ 0.7 ​ (0.6) ​ (0.7) ​ (1.6) Pension components ​ ​ (0.6) ​ ​ (0.9) ​ ​ (1.8) ​ ​ (2.2) Other ​ ​ — ​ ​ 0.1 ​ ​ — ​ ​ 0.6 Interest and other income (expense), net ​ $ (4.6) ​ $ (3.7) ​ $ (14.0) ​ $ (11.5) ​

Business Segment Information

Business Segment Information	9 Months Ended
	Sep. 30, 2019
Business Segment Information
Business Segment Information	18. Business Segment Information ​ The Company has two reportable segments, BSI and BEST, as discussed in Note 1 to the unaudited condensed consolidated financial statements. ​ Revenue and operating income by reportable segment for the three and nine months ended September 30, 2019 and 2018 are presented below (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2019 2018 2019 2018 Revenue: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ BSI ​ $ 471.8 ​ $ 417.1 ​ $ 1,331.0 ​ $ 1,206.5 BEST ​ 52.5 ​ 50.9 ​ 152.2 ​ 139.2 Eliminations (a) ​ (3.2) ​ (1.4) ​ (10.5) ​ (3.7) Total revenue ​ $ 521.1 ​ $ 466.6 ​ $ 1,472.7 ​ $ 1,342.0 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Income (loss) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ BSI ​ $ 84.0 ​ $ 63.6 ​ $ 173.3 ​ $ 146.5 BEST ​ 3.7 ​ 5.4 ​ 9.9 ​ 9.3 Corporate, eliminations and other (b) ​ 0.1 ​ 0.1 ​ — ​ 0.2 Total operating income ​ $ 87.8 ​ $ 69.1 ​ $ 183.2 ​ $ 156.0 (a) Represents product and service revenue between reportable segments. (b) Represents corporate costs and eliminations not allocated to the reportable segments. ​ Total assets by reportable segment as of September 30, 2019 and December 31, 2018 are as follows (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, December 31, ​ 2019 2018 Assets: ​ ​ ​ ​ ​ ​ BSI ​ $ 2,296.5 ​ $ 2,100.6 BEST ​ 59.2 ​ 33.2 Eliminations and other (a) ​ (3.6) ​ (5.2) Total assets ​ $ 2,352.1 ​ $ 2,128.6 (a) Assets not allocated to the reportable segments and eliminations of intercompany transactions.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2019
Recent Accounting Pronouncements
Recent Accounting Pronouncements	19. Recent Accounting Pronouncements ​ In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820), Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement , which modifies the disclosure requirements of fair value measurements, including the consideration of costs and benefits. This ASU is effective for the Company in fiscal years beginning after December 15, 2019. The adoption of this ASU is not expected to have a material impact on the Company's consolidated financial statements. ​ In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815) ​ In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. ​

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2019
Subsequent Events
Subsequent Events	20. Subsequent Events ​ On October 1, 2019, the Company acquired the electron paramagnetic resonance (“EPR”) business of Magnettech GmbH (“Magnettech”), a privately held Company, for a purchase price of Euro 8.5 million (approximately $9.3 million). Magnettech is a leading provider of benchtop electron paramagnetic resonance systems and EPR accessories. Magnettech is located in Freiberg, Germany and will be integrated into the Bruker BioSpin Group within the BSI Segment. The purchase accounting for this acquisition will be finalized within the measurement period. ​ On October 31, 2019, Bruker Corporation signed a purchase and sale agreement to acquire the land and buildings at 15 Fortune Drive and 44 Manning Road, both in Billerica, MA, for a total purchase price of $12.3 million, from a trust controlled equally by Bruker’s President and CEO, Frank Laukien, and his half-brother, Dirk D. Laukien. The price for the properties is based on an independent third-party appraisal and arms-length negotiations with the sellers. The properties are located adjacent to the Company’s corporate headquarters at 40 Manning Road, Billerica, MA which is already a corporate asset. One of the properties, 15 Fortune Drive, is currently leased by the Company and the other property, 40 Manning Road, is leased to third parties. ​ These purchase are part of the Company’s plan to expand its corporate campus in Billerica for future business growth. Subject to satisfactory due diligence and customary closing conditions, the transaction is expected to close in the first quarter of 2020.

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2019
Revenue
Schedule of revenues disaggregated by Group, end customer geographical location and timing of recognition	The following table presents the Company’s revenues by Group and End Customer Geography (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, ​ 2019 2018 2019 2018 Revenue by Group: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Bruker BioSpin $ 143.7 ​ $ 139.5 $ 422.4 ​ $ 411.2 Bruker CALID ​ 158.2 ​ ​ 134.6 ​ 446.9 ​ ​ 393.9 Bruker Nano ​ 169.9 ​ ​ 143.0 ​ 461.7 ​ ​ 401.4 BEST ​ 52.5 ​ ​ 50.9 ​ 152.2 ​ ​ 139.2 Eliminations ​ (3.2) ​ ​ (1.4) ​ (10.5) ​ ​ (3.7) Total revenue ​ $ 521.1 ​ $ 466.6 ​ $ 1,472.7 ​ $ 1,342.0 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, ​ 2019 2018 2019 2018 Revenue by End Customer Geography: ​ ​ ​ ​ ​ ​ ​ ​ United States $ 135.5 ​ $ 134.1 $ 379.3 ​ $ 347.3 Germany ​ 57.7 ​ ​ 44.9 ​ 150.1 ​ ​ 135.3 Rest of Europe ​ 121.0 ​ ​ 114.6 ​ 350.0 ​ ​ 346.4 Asia Pacific ​ 158.5 ​ ​ 134.4 ​ 464.5 ​ ​ 396.8 Other ​ 48.4 ​ ​ 38.6 ​ 128.8 ​ ​ 116.2 Total revenue ​ $ 521.1 ​ $ 466.6 ​ $ 1,472.7 ​ $ 1,342.0 ​ Revenue for the Company recognized at a point in time versus over time is as follows (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, ​ 2019 2018 2019 2018 Revenue recognized at a point in time $ 463.8 ​ $ 427.1 $ 1,310.2 ​ $ 1,227.6 Revenue recognized over time ​ 57.3 ​ ​ 39.5 ​ 162.5 ​ ​ 114.4 Total revenue $ 521.1 ​ $ 466.6 $ 1,472.7 ​ $ 1,342.0

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2019
Rave
Acquisitions
Components and fair value allocation of the consideration transferred in connection with acquisitions	The components and fair value allocation of the consideration transferred in connection with the acquisition were as follows (dollars in millions): ​ ​ ​ ​ ​ Consideration Transferred: ​ Cash paid $ 55.8 Contingent consideration ​ 4.4 Working capital adjustment ​ ​ (3.6) Total consideration transferred ​ $ 56.6 ​ ​ ​ ​ Allocation of Consideration Transferred: ​ Inventories ​ $ 23.1 Accounts receivable ​ 2.2 Other current and non-current assets ​ 0.8 Property, plant and equipment ​ 2.1 Operating lease assets ​ 1.0 Intangible assets: ​ ​ Technology ​ 17.9 Customer relationships ​ 15.5 Trade name ​ 1.5 Goodwill ​ 6.4 Liabilities assumed ​ (13.9) Total consideration allocated ​ $ 56.6
2019 Acquisitions
Acquisitions
Schedule of consideration transferred and the respective reporting segment for each acquisition	​ The following table reflects the consideration transferred and the respective reporting segment for each of these acquisitions: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Name of Acquisition Date Acquired Segment Consideration Cash Consideration Arxspan, LLC ​ March 4, 2019 BSI ​ $ 16.6 ​ $ 14.4 Ampegon PPT GmbH ​ March 7, 2019 BEST ​ 2.0 ​ 2.0 PMOD Technologies GmbH ​ July 1, 2019 ​ BSI ​ ​ 8.9 ​ ​ 7.9 ​ ​ ​ ​ ​ ​ $ 27.5 ​ $ 24.3
2018 Acquisitions
Acquisitions
Components and fair value allocation of the consideration transferred in connection with acquisitions	The following acquisitions occurred in the nine months ended September 30, 2018 (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ Company Acquired Anasys ​ JPK Reportable segment assigned BSI BSI Consideration Transferred: ​ ​ ​ ​ ​ ​ Cash paid ​ $ 27.0 ​ $ 16.6 Cash acquired ​ — ​ ​ (0.2) Contingent consideration ​ 5.3 ​ ​ 4.3 Total consideration transferred ​ $ 32.3 ​ $ 20.7 ​ ​ ​ ​ ​ ​ ​ Allocation of Consideration Transferred: ​ ​ ​ ​ Inventories ​ $ 2.8 ​ $ 3.0 Accounts receivable ​ ​ 0.8 ​ ​ 1.8 Other current and non-current assets ​ 1.1 ​ ​ 0.7 Intangible assets: ​ ​ ​ ​ Technology ​ 7.3 ​ ​ 7.0 Customer relationships ​ ​ 8.0 ​ ​ 7.5 Backlog ​ ​ 1.8 ​ ​ 1.1 Trade name ​ 0.6 ​ ​ 0.6 Goodwill ​ 16.6 ​ ​ 8.0 Deferred taxes, net ​ (3.2) ​ ​ (4.9) Liabilities assumed ​ (3.5) ​ ​ (4.1) Total consideration allocated ​ $ 32.3 ​ $ 20.7

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2019
Stock-Based Compensation
Stock-based compensation expense, by award	The Company recorded stock-based compensation expense as follows in the unaudited condensed consolidated statements of income and comprehensive income (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2019 2018 2019 2018 Stock options ​ $ 0.7 ​ $ 1.2 ​ $ 2.1 ​ $ 3.2 Restricted stock awards ​ 0.1 ​ 0.3 ​ 0.3 ​ 0.7 Restricted stock units ​ ​ 2.7 ​ ​ 1.8 ​ ​ 6.3 ​ ​ 4.3 Total stock-based compensation ​ $ 3.5 ​ $ 3.3 ​ $ 8.7 ​ $ 8.2
Stock-based compensation expense, cost allocation	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2019 2018 2019 2018 Costs of product revenue ​ $ 0.5 ​ $ 0.5 ​ $ 1.3 ​ $ 1.2 Selling, general and administrative ​ 2.5 ​ 2.3 ​ 6.1 ​ 5.8 Research and development ​ ​ 0.5 ​ ​ 0.5 ​ ​ 1.3 ​ ​ 1.2 Total stock-based compensation ​ $ 3.5 ​ $ 3.3 ​ $ 8.7 ​ $ 8.2
Assumptions regarding volatility, expected life, dividend yield and risk-free interest rates	​ ​ ​ ​ ​ ​ ​ ​ 2019 2018 Risk-free interest rates 1.55 % 2.80 % Expected life 5.33 years 5.38 years Volatility 29.57 % 28.46 % Expected dividend yield 0.38 % 0.47 %
Schedule of stock option activity	Stock option activity for the nine months ended September 30, 2019 was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ ​ ​ ​ Weighted ​ Remaining ​ Aggregate ​ ​ Shares Subject ​ Average ​ Contractual ​ Intrinsic Value ​ to Options Option Price Term (Yrs) (in millions) (b) Outstanding at December 31, 2018 2,593,310 ​ $ 21.41 ​ ​ ​ ​ ​ Granted ​ 112,232 ​ ​ 44.17 ​ ​ ​ ​ ​ Exercised (465,701) ​ 19.27 ​ ​ ​ ​ ​ Forfeited/Expired (85,340) ​ 22.35 ​ ​ ​ ​ ​ Outstanding at September 30, 2019 2,154,501 ​ $ 23.03 5.1 ​ $ 45.2 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Exercisable at September 30, 2019 1,544,782 ​ $ 20.49 4.8 ​ $ 36.2 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Exercisable and expected to vest at September 30, 2019 (a) 2,103,772 ​ $ 22.87 5.1 ​ $ 44.4 (a) In addition to the options that are vested at September 30, 2019, the Company expects a portion of the unvested options to vest in the future. Options expected to vest in the future are determined by applying an estimated forfeiture rate to the options that are unvested as of September 30, 2019. (b) The aggregate intrinsic value is based on the positive difference between the fair value of the Company’s common stock price of $43.93 on September 30, 2019 and the exercise price of the underlying stock options.
Restricted stock awards
Stock-Based Compensation
Schedule of restricted stock award and restricted stock unit activity	Restricted stock award activity for the nine months ended September 30, 2019 was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average Grant ​ ​ Shares Subject ​ Date Fair ​ to Restriction Value Outstanding at December 31, 2018 ​ 24,633 ​ $ 19.82 Vested (24,633) ​ 19.82 Outstanding at September 30, 2019 — ​ $ — ​
Restricted stock units
Stock-Based Compensation
Schedule of restricted stock award and restricted stock unit activity	Restricted stock unit activity for the nine months ended September 30, 2019 was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average Grant ​ ​ Shares Subject ​ Date Fair ​ to Restriction Value Outstanding at December 31, 2018 806,249 ​ $ 29.88 Granted ​ 346,462 ​ ​ 40.66 Vested (213,286) ​ 31.14 Forfeited ​ (32,482) ​ ​ 29.20 Outstanding at September 30, 2019 906,943 ​ $ 33.73

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2019
Earnings Per Share
Computation of basic and diluted weighted average shares outstanding and net income per common share	The following table sets forth the computation of basic and diluted weighted average shares outstanding and net income per common share attributable to Bruker shareholders (dollars in millions, except per share amounts): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2019 2018 2019 2018 Net income attributable to Bruker Corporation, as reported ​ $ 61.3 ​ $ 43.4 ​ $ 128.6 ​ $ 101.6 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average shares outstanding: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average shares outstanding-basic ​ 154.2 ​ 156.4 ​ 155.7 ​ 156.1 Effect of dilutive securities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Stock options and restricted stock awards and units ​ 1.4 ​ 1.0 ​ 1.3 ​ 1.1 ​ ​ 155.6 ​ 157.4 ​ 157.0 ​ 157.2 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net income per common share attributable to Bruker Corporation shareholders: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic ​ $ 0.40 ​ $ 0.28 ​ $ 0.83 ​ $ 0.65 Diluted ​ $ 0.39 ​ $ 0.28 ​ $ 0.82 ​ $ 0.65

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2019
Fair Value of Financial Instruments
Schedule of financial instruments measured at fair value on a recurring basis	The following tables set forth the Company's financial instruments that are measured at fair value on a recurring basis and presents them within the fair value hierarchy using the lowest level of input that is significant to the fair value measurement at September 30, 2019 and December 31, 2018 (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Quoted Prices Significant ​ ​ ​ ​ ​ ​ ​ ​ in Active ​ Other ​ Significant ​ ​ ​ ​ ​ Markets ​ Observable ​ Unobservable ​ ​ ​ ​ ​ Available ​ Inputs ​ Inputs September 30, 2019 Total (Level 1) (Level 2) (Level 3) Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Embedded derivatives in purchase and delivery contracts ​ $ 0.3 ​ $ — ​ $ 0.3 ​ $ — Foreign exchange contracts ​ ​ 0.3 ​ ​ — ​ ​ 0.3 ​ ​ — Total assets recorded at fair value ​ $ 0.6 ​ $ — ​ $ 0.6 ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Contingent consideration ​ $ 15.5 ​ $ — ​ $ — ​ $ 15.5 Hybrid instrument liability ​ ​ 14.3 ​ ​ — ​ ​ — ​ ​ 14.3 Foreign exchange contracts ​ ​ 1.5 ​ ​ — ​ ​ 1.5 ​ ​ — Embedded derivatives in purchase and delivery contracts ​ ​ 0.8 ​ ​ — ​ ​ 0.8 ​ ​ — Fixed price commodity contracts ​ ​ 0.2 ​ ​ — ​ ​ 0.2 ​ ​ — Total liabilities recorded at fair value ​ $ 32.3 ​ $ — ​ $ 2.5 ​ $ 29.8 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Quoted Prices Significant ​ ​ ​ ​ ​ ​ ​ ​ in Active ​ Other ​ Significant ​ ​ ​ ​ ​ Markets ​ Observable ​ Unobservable ​ ​ ​ ​ ​ Available ​ Inputs ​ Inputs December 31, 2018 Total (Level 1) (Level 2) (Level 3) Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Foreign exchange contracts ​ $ 0.2 ​ $ — ​ $ 0.2 ​ $ — Embedded derivatives in purchase and delivery contracts ​ ​ 0.4 ​ ​ — ​ ​ 0.4 ​ ​ — Total assets recorded at fair value ​ $ 0.6 ​ $ — ​ $ 0.6 ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Contingent consideration ​ $ 15.1 ​ $ — ​ $ — ​ $ 15.1 Hybrid instrument liability ​ ​ 12.9 ​ ​ — ​ ​ — ​ ​ 12.9 Foreign exchange contracts ​ ​ 2.8 ​ ​ — ​ ​ 2.8 ​ ​ — Embedded derivatives in purchase and delivery contracts ​ 0.9 ​ — ​ 0.9 ​ — Fixed price commodity contracts ​ ​ 0.5 ​ ​ — ​ ​ 0.5 ​ ​ — Total liabilities recorded at fair value ​ $ 32.2 ​ $ — ​ $ 4.2 ​ $ 28.0
Schedule of changes in contingent consideration liabilities	​ The following table sets forth the changes in contingent consideration liabilities for the nine months ended September 30, 2019 (dollars in millions): ​ ​ ​ ​ ​ Balance at December 31, 2018 $ 15.1 Current period additions ​ 5.4 Current period adjustments ​ 1.4 Current period settlements ​ (6.1) Foreign currency effect ​ (0.3) Balance at September 30, 2019 ​ $ 15.5
Schedule of changes in hybrid instrument liability	The following table sets forth the changes in hybrid instrument liability for the nine months ended September 30, 2019 (dollars in millions): ​ ​ ​ ​ ​ Balance at December 31, 2018 $ 12.9 Current period adjustments ​ ​ 1.4 Balance at September 30, 2019 ​ $ 14.3

Restricted Cash (Tables)

Restricted Cash (Tables)	9 Months Ended
	Sep. 30, 2019
Restricted Cash
Schedule of increase in cash flow statement balances due to inclusion of restricted cash	The inclusion of restricted cash increased the balances of the unaudited condensed consolidated statement of cash flows as follows (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, ​ 2019 2018 Beginning Balance ​ $ 3.9 ​ $ 3.9 Ending Balance ​ 3.7 ​ 4.7

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2019
Inventories
Schedule of inventories	Inventories consisted of the following (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, December 31, ​ 2019 2018 Raw materials ​ $ 194.6 ​ $ 164.5 Work-in-process ​ 216.3 ​ 182.4 Finished goods ​ 101.8 ​ 94.8 Demonstration units ​ 74.0 ​ 67.9 Inventories ​ $ 586.7 ​ $ 509.6

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets
Schedule of changes in the carrying amount of goodwill	The following table sets forth the changes in the carrying amount of goodwill for the three months ended September 30, 2019 (dollars in millions): ​ ​ ​ ​ ​ Balance at December 31, 2018 $ 275.7 Current period additions ​ ​ 13.9 Current period adjustments ​ ​ (0.6) Foreign currency effect ​ ​ (6.7) Balance at September 30, 2019 ​ $ 282.3
Summary of intangible assets	The following is a summary of intangible assets, excluding goodwill (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2019 ​ December 31, 2018 ​ ​ Gross ​ ​ ​ ​ ​ ​ ​ Gross ​ ​ ​ ​ ​ ​ ​ ​ Carrying ​ Accumulated ​ Net Carrying ​ Carrying ​ Accumulated ​ Net Carrying ​ Amount Amortization Amount Amount Amortization Amount Existing technology and related patents ​ $ 294.4 ​ $ (175.0) ​ $ 119.4 ​ $ 272.6 ​ $ (160.5) ​ $ 112.1 Customer relationships ​ 131.1 ​ (27.1) ​ 104.0 ​ 112.0 ​ (18.1) ​ 93.9 Non compete contracts ​ 1.8 ​ (1.8) ​ — ​ ​ 1.8 ​ ​ (1.8) ​ ​ — Trade names ​ 13.2 ​ (2.5) ​ 10.7 ​ 11.6 ​ (1.6) ​ 10.0 Other ​ ​ 5.4 ​ ​ (5.2) ​ ​ 0.2 ​ ​ 5.1 ​ ​ (2.4) ​ ​ 2.7 Intangible assets ​ $ 445.9 ​ $ (211.6) ​ $ 234.3 ​ $ 403.1 ​ $ (184.4) ​ $ 218.7

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2019
Debt
Components of debt obligations	The Company’s debt obligations as of September 30, 2019 and December 31, 2018 consisted of the following (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, December 31, ​ 2019 2018 US Dollar revolving loan under the 2015 Credit Agreement ​ $ 310.4 ​ $ 111.6 US Dollar notes under the Note Purchase Agreement ​ 205.0 ​ 220.0 Unamortized debt issuance costs under the Note Purchase Agreement ​ ​ (0.4) ​ ​ (0.5) Other revolving loans ​ ​ — ​ ​ 2.9 Capital lease obligations and other loans ​ 3.8 ​ 7.1 Total debt ​ 518.8 ​ 341.1 Current portion of long-term debt ​ (0.3) ​ (18.5) Total long-term debt, less current portion ​ $ 518.5 ​ $ 322.6
Summary of maximum commitments and net amounts available under the 2015 Credit Agreement and other lines of credit	The following is a summary of the maximum commitments and the net amounts available to the Company under the 2015 Credit Agreement and other lines of credit with various financial institutions located primarily in Germany and Switzerland that are unsecured and typically due upon demand with interest payable monthly, at September 30, 2019 (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Total Amount ​ ​ Outstanding ​ ​ ​ ​ Average ​ Committed by ​ Outstanding ​ Letters of ​ Total Amount ​ Interest Rate Lenders Borrowings Credit Available 2015 Credit Agreement 2.5 % $ 500.0 ​ $ 310.4 ​ $ 1.1 ​ $ 188.5 Alicona revolving line of credit ​ — ​ ​ 5.3 ​ ​ — ​ ​ — ​ ​ 5.3 Other lines of credit — ​ 231.4 ​ — ​ 126.4 ​ 105.0 Total revolving lines of credit ​ ​ ​ $ 736.7 ​ $ 310.4 ​ $ 127.5 ​ $ 298.8

Derivative Instruments and He_2

Derivative Instruments and Hedging Activities (Tables)	9 Months Ended
	Sep. 30, 2019
Derivative Instruments and Hedging Activities
Schedule of notional amounts outstanding under foreign currency contracts	The Company had the following notional amounts outstanding under foreign exchange contracts at September 30, 2019 and December 31, 2018 (in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Notional ​ ​ ​ ​ ​ Notional ​ ​ ​ ​ ​ ​ ​ ​ Amount in Buy ​ ​ ​ ​ ​ Amount in U.S. ​ Fair Value of ​ Fair Value of Buy Currency Sell Maturity Dollars Assets Liabilities September 30, 2019: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Euro ​ 17.9 ​ U.S. Dollars ​ October 2019 ​ $ 20.1 ​ $ — ​ $ 0.6 Great Britain Pound ​ 8.1 ​ Euro ​ October 2019 ​ ​ 9.7 ​ ​ 0.3 ​ ​ — Swiss Francs ​ 9.4 ​ Japanese Yen ​ October 2019 ​ ​ 9.6 ​ ​ — ​ ​ 0.1 Swiss Francs ​ 7.7 ​ U.S. Dollars ​ October 2019 ​ ​ 7.9 ​ ​ — ​ ​ 0.2 Euro ​ 6.5 ​ Great Britain Pound ​ October 2019 to October 2020 ​ ​ 7.2 ​ ​ — ​ ​ 0.1 Taiwan Dollar ​ 204.0 ​ U.S. Dollars ​ October 2019 ​ ​ 6.6 ​ ​ — ​ ​ 0.1 Chinese Renminbi ​ 72.3 ​ U.S. Dollars ​ October 2019 ​ ​ 10.5 ​ ​ — ​ ​ 0.4 Euro ​ 2.9 ​ Chinese Renminbo ​ October 2019 ​ ​ 3.1 ​ ​ — ​ ​ — Singapore Dollar ​ 4.2 ​ U.S. Dollars ​ October 2019 ​ ​ 3.1 ​ ​ — ​ ​ — Singapore Dollar ​ 2.8 ​ Euro ​ October 2019 ​ ​ 2.0 ​ ​ — ​ ​ — Swedish Krona ​ 26.7 ​ Euro ​ October 2019 ​ ​ 2.7 ​ ​ — ​ ​ — ​ ​ ​ ​ ​ ​ ​ ​ $ 82.5 ​ $ 0.3 ​ $ 1.5 December 31, 2018: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Euro ​ 25.4 ​ U.S. Dollars ​ January 2019 ​ $ 31.1 ​ $ — ​ $ 2.1 U.S. Dollars ​ 8.5 Euro January 2019 ​ 8.6 ​ — ​ 0.1 Swiss Francs ​ 11.1 ​ U.S. Dollars ​ January 2019 ​ ​ 11.3 ​ ​ — ​ ​ — U.S. Dollars ​ 2.1 ​ Swiss Francs ​ January 2019 ​ ​ 2.1 ​ ​ — ​ ​ — Swiss Francs ​ 10.4 ​ Japanese Yen ​ April 2019 ​ ​ 10.8 ​ ​ — ​ ​ 0.2 U.S. Dollars ​ 1.5 ​ Canadian Dollars ​ January 2019 ​ ​ 1.5 ​ ​ — ​ ​ — Singapore Dollar ​ 4.3 ​ U.S. Dollars ​ January 2019 ​ ​ 3.1 ​ ​ — ​ ​ — Chinese Renminbi ​ 41.1 ​ U.S. Dollars ​ January 2019 ​ ​ 5.9 ​ ​ 0.1 ​ ​ — Great Britian Pound ​ 15.4 ​ Euro ​ January 2019 ​ ​ 20.0 ​ ​ — ​ ​ 0.4 Euro ​ 6.9 ​ Great Britian Pound ​ May 2019 to October 2020 ​ ​ 8.0 ​ ​ 0.1 ​ ​ — ​ ​ ​ ​ ​ ​ ​ ​ $ 102.4 ​ $ 0.2 ​ $ 2.8
Schedule of fair value and balance sheet location of derivative instruments	The fair value of the derivative instruments described above is recorded in the unaudited condensed consolidated balance sheets for the periods as follows (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, December 31, ​ Balance Sheet Location 2019 2018 Derivative assets: ​ ​ ​ ​ ​ ​ ​ ​ Foreign exchange contracts Other current assets ​ $ 0.3 ​ $ 0.2 Embedded derivatives in purchase and delivery contracts ​ Other current assets ​ ​ 0.2 ​ ​ 0.2 Embedded derivatives in purchase and delivery contracts ​ Other long-term assets ​ ​ 0.1 ​ ​ 0.2 ​ ​ ​ ​ ​ ​ ​ ​ ​ Derivative liabilities: ​ ​ ​ ​ ​ ​ ​ ​ Foreign exchange contracts ​ Other current liabilities ​ $ 1.5 ​ $ 2.8 Embedded derivatives in purchase and delivery contracts ​ Other current liabilities ​ ​ 0.8 ​ ​ 0.9 Fixed price commodity contracts ​ Other current liabilities ​ ​ 0.2 ​ ​ 0.5
Schedule of impact on net income of unrealized gains and losses resulting from changes in the fair value of derivative instruments	The impact on net income of unrealized gains and losses resulting from changes in the fair value of derivative instruments not designated as hedging instruments are as follows (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2019 2018 2019 2018 Foreign exchange contracts ​ $ (1.0) ​ $ 1.4 ​ $ 1.3 ​ $ (6.7) Embedded derivatives in purchase and delivery contracts ​ (0.1) ​ — ​ — ​ 1.3 Fixed price commodity contracts ​ — ​ (0.3) ​ 0.3 ​ (1.2) Net impact to interest and other income (expense) ​ $ (1.1) ​ $ 1.1 ​ $ 1.6 ​ $ (6.6)

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2019
Leases
Schedule of lease cost	The components of lease cost for the three and nine months ended September 30, 2019 are as follows (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended Nine Months Ended ​ ​ September 30, 2019 ​ September 30, 2019 Amortization of right-of-use assets ​ $ 0.1 ​ $ 0.2 Interest on lease liabilities ​ — ​ — Total finance lease cost ​ $ 0.1 ​ $ 0.2 ​ ​ ​ ​ ​ ​ ​ Operating lease cost ​ $ 6.1 ​ $ 18.8 Short term lease cost ​ 0.5 ​ 1.6 Variable lease cost ​ 1.0 ​ 2.7 Sublease income ​ (0.3) ​ (0.9) Total lease cost ​ $ 7.4 ​ $ 22.4 ​
Schedule of supplemental balance sheet information	Supplemental balance sheet information as of September 30, 2019 related to leases was as follows (dollars in millions): ​ ​ ​ ​ ​ ​ ​ September 30, 2019 Operating leases ​ ​ ​ ​ Operating lease assets, net ​ $ 68.9 ​ Other current liabilities ​ 20.4 ​ Operating lease liability - long term ​ 50.7 ​ ​ ​ ​ ​ ​ Finance leases ​ ​ ​ ​ Property, plant and equipment, net ​ $ 1.5 ​ Current portion of long-term debt ​ 0.4 ​ Long-term debt ​ 1.0 ​ ​ ​ ​ ​ ​ Weighted average remaining lease term ​ ​ ​ ​ Operating leases ​ 5.2 years Finance leases ​ 3.5 years ​ ​ ​ ​ ​ Weighted average discount rate ​ ​ ​ ​ Operating leases ​ 2.5 % Finance leases ​ 2.8 %
Schedule of cash flow information	Supplemental cash flow information related to leases for the nine months ended September 30, 2019 was as follows (dollars in millions): ​ ​ ​ ​ ​ ​ Nine Months Ended ​ ​ September 30, 2019 ​ ​ ​ ​ Cash paid for amounts included in the measurement of lease liabilities ​ ​ ​ Operating cash flows from finance leases ​ $ — Operating cash flows from operating leases ​ 17.7 Financing cash flows from finance leases ​ 0.2 ​ ​ ​ ​ Right-of-use assets obtained in exchange for lease liabilities ​ ​ ​ Operating leases ​ $ 16.4 Finance leases ​ 0.8
Schedule of future minimum lease payments under non-cancellable operating leases	Future minimum lease payments under non-cancellable leases as of September 30, 2019 are as follows (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Leases Finance Leases 2019 (excluding the nine months ended September 30, 2019) ​ $ 5.9 ​ $ 0.1 2020 ​ 20.6 ​ 0.5 2021 ​ 15.2 ​ 0.4 2022 ​ 9.7 ​ 0.3 2023 ​ 7.6 ​ 0.2 Thereafter ​ 16.7 ​ — Total undiscounted lease payments ​ 75.7 ​ 1.5 Less: Imputed interest ​ (4.6) ​ (0.1) Total lease liabilities ​ $ 71.1 ​ $ 1.4 ​
Schedule of minimum commitments for the Company's operating leases as required under prior lease guidance	As of December 31, 2018, minimum commitments for the Company’s leases as required under prior lease guidance in ASC 840 were as follows (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Leases Finance Leases 2019 ​ $ 25.3 ​ $ — 2020 ​ 19.1 ​ 0.1 2021 ​ 13.7 ​ 0.1 2022 ​ 9.3 ​ — 2023 ​ 7.3 ​ — Thereafter ​ 18.4 ​ — Total ​ $ 93.1 ​ $ 0.2

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2019
Shareholders' Equity
Summary of comprehensive income (loss)	The following is a summary of comprehensive income (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2019 2018 2019 2018 Consolidated net income ​ $ 61.5 ​ $ 44.2 ​ $ 129.2 ​ $ 103.1 Foreign currency translation adjustments ​ (36.5) ​ (2.5) ​ (38.9) ​ (17.1) Pension liability adjustments, net of tax ​ 1.1 ​ 0.2 ​ 1.7 ​ 2.3 Net comprehensive income (loss) ​ 26.1 ​ 41.9 ​ 92.0 ​ 88.3 Less: Comprehensive income (loss) attributable to noncontrolling interests ​ 0.2 ​ 0.5 ​ 1.0 ​ 0.9 Less: Comprehensive income (loss) attributable to redeemable noncontrolling interest ​ ​ (1.2) ​ ​ — ​ ​ (1.8) ​ ​ — Comprehensive income (loss) attributable to Bruker Corporation ​ $ 27.1 ​ $ 41.4 ​ $ 92.8 ​ $ 87.4
Summary of the components of accumulated other comprehensive income (loss), net of tax	The following is a summary of the components of accumulated other comprehensive income, net of tax, at September 30, 2019 (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accumulated ​ ​ Foreign ​ Pension ​ Other ​ ​ Currency ​ Liability ​ Comprehensive ​ Translation Adjustment Income Balance at December 31, 2018 ​ $ 46.9 ​ $ (29.9) ​ $ 17.0 Other comprehensive income (loss) before reclassifications ​ ​ (37.6) ​ ​ 0.6 ​ ​ (37.0) Amounts reclassified from other comprehensive income (loss), net of tax of $0.2 million ​ ​ — ​ ​ 1.2 ​ ​ 1.2 Net current period other comprehensive income (loss) ​ ​ (37.6) ​ ​ 1.8 ​ ​ (35.8) Balance at September 30, 2019 ​ $ 9.3 ​ $ (28.1) ​ $ (18.8)

Other Charges, Net (Tables)

Other Charges, Net (Tables)	9 Months Ended
	Sep. 30, 2019
Other Charges, Net
Components of other charges, net	​ The components of other charges (gain), net were as follows (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2019 2018 2019 2018 Information technology transformation costs ​ $ 0.8 ​ $ 1.1 ​ $ 2.8 ​ $ 3.5 Restructuring charges ​ (7.4) ​ 2.0 ​ (5.5) ​ 5.9 Acquisition-related charges ​ ​ 0.9 ​ ​ 1.2 ​ ​ 5.9 ​ ​ 2.3 Other ​ 0.4 ​ 0.9 ​ 1.7 ​ 3.5 Other charges (gain), net ​ $ (5.3) ​ $ 5.2 ​ $ 4.9 ​ $ 15.2
Summary of restructuring charges	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2019 2018 2019 2018 Cost of revenues $ 0.6 $ 0.5 ​ $ 4.1 $ 0.8 Other charges, net ​ (7.4) ​ 2.0 ​ ​ (5.5) ​ 5.9 ​ ​ $ (6.8) ​ $ 2.5 ​ $ (1.4) ​ $ 6.7 ​
Schedule of changes in restructuring reserves	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Provisions ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ for Excess ​ Total Severance Exit Costs Inventory Balance at December 31, 2018 ​ $ 7.3 ​ $ 2.0 ​ $ 1.4 ​ $ 3.9 Restructuring charges ​ (1.4) ​ 4.1 ​ (5.9) ​ 0.4 Cash payments ​ (5.3) ​ (4.1) ​ (1.2) ​ — Other, non-cash adjustments and foreign currency effect ​ ​ 4.1 ​ ​ (0.5) ​ ​ 5.9 ​ ​ (1.3) Balance at September 30, 2019 ​ $ 4.7 ​ $ 1.5 ​ $ 0.2 ​ $ 3.0

Interest and Other Income (Ex_2

Interest and Other Income (Expense), Net (Tables)	9 Months Ended
	Sep. 30, 2019
Interest and Other Income (Expense), Net
Components of interest and other income (expense), net	​ The components of interest and other income (expense), net, were as follows (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2019 2018 2019 2018 Interest expense, net ​ $ (4.7) ​ $ (2.3) ​ $ (11.5) ​ $ (8.3) Exchange (losses) gains on foreign currency transactions ​ 0.7 ​ (0.6) ​ (0.7) ​ (1.6) Pension components ​ ​ (0.6) ​ ​ (0.9) ​ ​ (1.8) ​ ​ (2.2) Other ​ ​ — ​ ​ 0.1 ​ ​ — ​ ​ 0.6 Interest and other income (expense), net ​ $ (4.6) ​ $ (3.7) ​ $ (14.0) ​ $ (11.5)

Business Segment Information (T

Business Segment Information (Tables)	9 Months Ended
	Sep. 30, 2019
Business Segment Information
Schedule of revenue, operating income and total assets by reportable segment	​ Revenue and operating income by reportable segment for the three and nine months ended September 30, 2019 and 2018 are presented below (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2019 2018 2019 2018 Revenue: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ BSI ​ $ 471.8 ​ $ 417.1 ​ $ 1,331.0 ​ $ 1,206.5 BEST ​ 52.5 ​ 50.9 ​ 152.2 ​ 139.2 Eliminations (a) ​ (3.2) ​ (1.4) ​ (10.5) ​ (3.7) Total revenue ​ $ 521.1 ​ $ 466.6 ​ $ 1,472.7 ​ $ 1,342.0 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Income (loss) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ BSI ​ $ 84.0 ​ $ 63.6 ​ $ 173.3 ​ $ 146.5 BEST ​ 3.7 ​ 5.4 ​ 9.9 ​ 9.3 Corporate, eliminations and other (b) ​ 0.1 ​ 0.1 ​ — ​ 0.2 Total operating income ​ $ 87.8 ​ $ 69.1 ​ $ 183.2 ​ $ 156.0 (a) Represents product and service revenue between reportable segments. (b) Represents corporate costs and eliminations not allocated to the reportable segments. ​ Total assets by reportable segment as of September 30, 2019 and December 31, 2018 are as follows (dollars in millions): ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, December 31, ​ 2019 2018 Assets: ​ ​ ​ ​ ​ ​ BSI ​ $ 2,296.5 ​ $ 2,100.6 BEST ​ 59.2 ​ 33.2 Eliminations and other (a) ​ (3.6) ​ (5.2) Total assets ​ $ 2,352.1 ​ $ 2,128.6 (a) Assets not allocated to the reportable segments and eliminations of intercompany transactions.

Description of Business (Detail

Description of Business (Details) - segment	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Description of Business
Number of reportable segments			2
BSI
Description of Business
Segment revenue (as a percent)	90.50%	89.40%	90.40%	89.90%
Number of operating segments			3

Revenue - Disaggregation (Detai

Revenue - Disaggregation (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenues disaggregated by Group
Revenue	$ 521.1	$ 466.6	$ 1,472.7	$ 1,342
Revenue recognized at a point in time
Revenues disaggregated by Group
Revenue	463.8	427.1	1,310.2	1,227.6
Revenue recognized over time
Revenues disaggregated by Group
Revenue	57.3	39.5	162.5	114.4
United States
Revenues disaggregated by Group
Revenue	135.5	134.1	379.3	347.3
Germany
Revenues disaggregated by Group
Revenue	57.7	44.9	150.1	135.3
Rest of Europe
Revenues disaggregated by Group
Revenue	121	114.6	350	346.4
Asia Pacific
Revenues disaggregated by Group
Revenue	158.5	134.4	464.5	396.8
Other
Revenues disaggregated by Group
Revenue	48.4	38.6	128.8	116.2
Bruker BioSpin
Revenues disaggregated by Group
Revenue	143.7	139.5	422.4	411.2
Bruker CALID
Revenues disaggregated by Group
Revenue	158.2	134.6	446.9	393.9
Bruker Nano
Revenues disaggregated by Group
Revenue	169.9	143	461.7	401.4
BEST
Revenues disaggregated by Group
Revenue	52.5	50.9	152.2	139.2
Eliminations
Revenues disaggregated by Group
Revenue	$ (3.2)	$ (1.4)	$ (10.5)	$ (3.7)

Revenue - Remaining Performance

Revenue - Remaining Performance Obligations (Details) $ in Millions	Sep. 30, 2019USD ($)
Remaining Performance Obligations
Amount of remaining performance obligations	$ 1,520.5
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01
Remaining Performance Obligations
Remaining performance obligation expected to be recognized in the given period (as a percent)	63.60%
Duration of expected recognition period for remaining performance obligation	12 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 | Minimum
Remaining Performance Obligations
Duration of expected recognition period for remaining performance obligation	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 | Maximum
Remaining Performance Obligations
Duration of expected recognition period for remaining performance obligation	5 years

Revenue - Contract Balances (De

Revenue - Contract Balances (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Revenue
Contract assets	$ 38.1	$ 25.9
Contract liabilities	295.1	$ 288.5
Revenue recognition during the period	$ 165

Acquisitions - Rave LLC (Detail

Acquisitions - Rave LLC (Details) - USD ($) $ in Millions	Apr. 02, 2019	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Acquisitions
Purchase price		$ 79	$ 55.3
Allocation of Consideration Transferred:
Operating lease assets		68.9
Goodwill		$ 282.3		$ 275.7
Rave
Acquisitions
Amortization period for intangible assets acquired	10 years
Consideration Transferred:
Cash paid	$ 55.8
Contingent consideration	4.4
Working capital adjustment	(3.6)
Total consideration transferred	56.6
Allocation of Consideration Transferred:
Inventories	23.1
Accounts receivable	2.2
Other current and non-current assets	0.8
Property, plant and equipment	2.1
Operating lease assets	1
Goodwill	6.4
Liabilities assumed	(13.9)
Total consideration allocated	56.6
Rave | Technology
Allocation of Consideration Transferred:
Intangible assets	17.9
Rave | Customer relationships
Allocation of Consideration Transferred:
Intangible assets	15.5
Rave | Trade names
Allocation of Consideration Transferred:
Intangible assets	$ 1.5

Acquisitions - Additional infor

Acquisitions - Additional information (Details) - USD ($) $ in Millions	Apr. 02, 2019	Sep. 30, 2019	Sep. 30, 2018
Acquisitions
Cash Consideration		$ 79	$ 55.3
2019 Acquisitions
Acquisitions
Consideration	$ 52.2	27.5
Maximum additional consideration	$ 5
Cash Consideration		24.3
Arxspan, LLC
Acquisitions
Consideration		16.6
Cash Consideration		14.4
Ampegon PPT GmbH
Acquisitions
Consideration		2
Cash Consideration		2
PMOD Technologies GmbH Member
Acquisitions
Consideration		8.9
Cash Consideration		$ 7.9

Acquisitions - Anasys and JPK (

Acquisitions - Anasys and JPK (Details) € in Millions, $ in Millions	Jul. 11, 2018USD ($)	Jul. 11, 2018EUR (€)	Apr. 08, 2018USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)
Acquisitions
Purchase price				$ 79	$ 55.3
Allocation of Consideration Transferred:
Goodwill				$ 282.3		$ 275.7
Anasys Instruments Corp
Acquisitions
Ownership percentage acquired			100.00%
Purchase price			$ 27
Maximum additional consideration			9.6
Contingent consideration			5.3
Consideration Transferred:
Cash paid			27
Contingent consideration			5.3
Total consideration transferred			32.3
Allocation of Consideration Transferred:
Inventories			2.8
Accounts receivable			0.8
Other current and non-current assets			1.1
Goodwill			16.6
Deferred taxes, net			(3.2)
Liabilities assumed			(3.5)
Total consideration allocated			$ 32.3
Amortization period for intangible assets acquired			8 years
Anasys Instruments Corp | Customer relationships
Allocation of Consideration Transferred:
Intangible assets			$ 8
Anasys Instruments Corp | Technology
Allocation of Consideration Transferred:
Intangible assets			7.3
Anasys Instruments Corp | Backlog
Allocation of Consideration Transferred:
Intangible assets			$ 1.8
Amortization period for intangible assets acquired			1 year
Anasys Instruments Corp | Trade names
Allocation of Consideration Transferred:
Intangible assets			$ 0.6
JPK Instruments AG
Acquisitions
Ownership percentage acquired	100.00%
Purchase price	$ 16.6	€ 14.2
Maximum additional consideration	5	€ 4.3
Contingent consideration	4.3
Consideration Transferred:
Cash paid	16.6
Cash acquired	(0.2)
Contingent consideration	4.3
Total consideration transferred	20.7
Allocation of Consideration Transferred:
Inventories	3
Accounts receivable	1.8
Other current and non-current assets	0.7
Goodwill	8
Deferred taxes, net	(4.9)
Liabilities assumed	(4.1)
Total consideration allocated	$ 20.7
Amortization period for intangible assets acquired	8 years	8 years
JPK Instruments AG | Customer relationships
Allocation of Consideration Transferred:
Intangible assets	$ 7.5
JPK Instruments AG | Technology
Allocation of Consideration Transferred:
Intangible assets	7
JPK Instruments AG | Backlog
Allocation of Consideration Transferred:
Intangible assets	$ 1.1
Amortization period for intangible assets acquired	1 year	1 year
JPK Instruments AG | Trade names
Allocation of Consideration Transferred:
Intangible assets	$ 0.6

Stock-Based Compensation - Plan

Stock-Based Compensation - Plan Information (Details) - shares	May 14, 2010	Sep. 30, 2019
2010 Plan
Stock-Based Compensation
Common stock authorized for issuance (in shares)	8,000,000	0
2010 Plan | Minimum
Stock-Based Compensation
Vesting period	3 years
2010 Plan | Maximum
Stock-Based Compensation
Vesting period	5 years
2016 Plan
Stock-Based Compensation
Common stock authorized for issuance (in shares)		9,500,000
2016 Plan | Minimum
Stock-Based Compensation
Vesting period		1 year
2016 Plan | Maximum
Stock-Based Compensation
Vesting period		4 years

Stock-Based Compensation - Expe

Stock-Based Compensation - Expense (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Stock-Based Compensation
Total stock-based compensation	$ 3.5	$ 3.3	$ 8.7	$ 8.2
Costs of product revenue
Stock-Based Compensation
Total stock-based compensation	0.5	0.5	1.3	1.2
Selling, general and administrative
Stock-Based Compensation
Total stock-based compensation	2.5	2.3	6.1	5.8
Research and development
Stock-Based Compensation
Total stock-based compensation	0.5	0.5	1.3	1.2
Mestrelab Research, S.L
Stock-Based Compensation
Total stock-based compensation	0.6		1.4
Stock options
Stock-Based Compensation
Total stock-based compensation	0.7	1.2	2.1	3.2
Restricted stock awards
Stock-Based Compensation
Total stock-based compensation	0.1	0.3	0.3	0.7
Restricted stock units
Stock-Based Compensation
Total stock-based compensation	$ 2.7	$ 1.8	$ 6.3	$ 4.3

Stock-Based Compensation - Assu

Stock-Based Compensation - Assumptions (Details) - Stock options	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Stock-Based Compensation
Risk-free interest rates (as a percent)	1.55%	2.80%
Expected life	5 years 3 months 29 days	5 years 4 months 17 days
Volatility (as a percent)	29.57%	28.46%
Expected dividend yield (as a percent)	0.38%	0.47%

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Option Activity (Details) - Stock options - USD ($)	9 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Sep. 30, 2018
Stock options, Shares Subject to Options
Outstanding at the beginning of the period (in shares)		2,593,310
Granted (in shares)		112,232
Exercised (in shares)		(465,701)
Forfeited /Expired (in shares)		(85,340)
Outstanding at the end of the period (in shares)		2,154,501
Exercisable at the end of the period (in shares)		1,544,782
Exercisable and expected to vest at the end of the period (in shares)		2,103,772
Stock options, Weighted Average Option Price
Outstanding at the beginning of the period (in dollars per share)		$ 21.41
Granted (in dollars per share)		44.17
Exercised (in dollars per share)		19.27
Forfeited (in dollars per share)		22.35
Outstanding at the end of the period (in dollars per share)		23.03
Exercisable at the end of the period (in dollars per share)		20.49
Exercisable and expected to vest at the end of the period (in dollars per share)		$ 22.87
Stock options, additional information
Weighted Average Remaining Contractual Term, Outstanding		5 years 1 month 6 days
Weighted Average Remaining Contractual Term, Exercisable		4 years 9 months 18 days
Weighted Average Remaining Contractual Term, Exercisable and expected to vest		5 years 1 month 6 days
Aggregate Intrinsic Value, Outstanding		$ 45.2
Aggregate Intrinsic Value, Exercisable		36.2
Aggregate Intrinsic Value, Exercisable and expected to vest		$ 44.4
Fair value of the Company's common stock price (in dollars per share)		$ 43.93
Weighted average fair values of options granted (in dollars per share)	$ 11.16		$ 9.50
Intrinsic value of options exercised		$ 10,300,000	$ 7,200,000
Minimum
Stock-Based Compensation
Vesting period		3 years
Maximum
Stock-Based Compensation
Vesting period		4 years

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Award and RSU Activity (Details) - USD ($) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Restricted stock awards
Restricted stock, Shares Subject to Restriction
Outstanding at the beginning of the period (in shares)	24,633
Vested (in shares)	(24,633)
Restricted stock, Weighted Average Grant Date Fair Value
Outstanding at the beginning of the period (in dollars per share)	$ 19.82
Vested (in dollars per share)	$ 19.82
Additional share-based compensation disclosures
Total fair value of shares vested	$ 1	$ 1.1
Restricted stock units
Restricted stock, Shares Subject to Restriction
Outstanding at the beginning of the period (in shares)	806,249
Granted (in shares)	346,462
Vested (in shares)	(213,286)
Forfeited (in shares)	(32,482)
Outstanding at the end of the period (in shares)	906,943
Restricted stock, Weighted Average Grant Date Fair Value
Outstanding at the beginning of the period (in dollars per share)	$ 29.88
Granted (in dollars per share)	40.66
Vested (in dollars per share)	31.14
Forfeited (in dollars per share)	29.20
Outstanding at the end of the period (in dollars per share)	$ 33.73
Additional share-based compensation disclosures
Total fair value of shares vested	$ 6.6	$ 3.7
Unrecognized pre-tax stock-based compensation expense	$ 24.9
Weighted average remaining service period	3 years

Stock-Based Compensation - Unre

Stock-Based Compensation - Unrecognized Compensation Expense (Details) $ in Millions	9 Months Ended
	Sep. 30, 2019USD ($)
Stock options
Stock-Based Compensation
Expected pre-tax stock-based compensation expense	$ 3.3
Weighted average remaining service period	2 years 6 months
Restricted stock units
Stock-Based Compensation
Expected pre-tax stock-based compensation expense	$ 24.9
Weighted average remaining service period	3 years

Earnings Per Share - Computatio

Earnings Per Share - Computation (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Earnings Per Share
Redemption value adjustment of the redeemable noncontrolling interest	$ 0	$ 0	$ 0	$ 0
Net income attributable to Bruker Corporation, as reported -basic	$ 61.3	$ 43.4	$ 128.6	$ 101.6
Weighted average shares outstanding:
Weighted average shares outstanding-basic	154.2	156.4	155.7	156.1
Effect of dilutive securities:
Stock options and restricted stock awards and units (in shares)	1.4	1	1.3	1.1
Weighted average shares outstanding-diluted	155.6	157.4	157	157.2
Net income per common share attributable to Bruker Corporation shareholders:
Basic (in dollars per share)	$ 0.40	$ 0.28	$ 0.83	$ 0.65
Diluted (in dollars per share)	$ 0.39	$ 0.28	$ 0.82	$ 0.65

Earnings Per Share - Anti-dilut

Earnings Per Share - Anti-dilutive Stock Options (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Stock options
Anti-dilutive securities
Number of shares excluded from the computation of diluted earnings per share	0.1	0.6	0.5	0.6

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Hierarchy (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Significant Other Observable Inputs (Level 2)
Liabilities:
Fair value of long-term fixed interest rate debt	$ 216.1	$ 228.8
Recurring basis
Assets:
Foreign exchange contracts	0.3	0.2
Embedded derivatives in purchase and delivery contracts	0.3	0.4
Total assets recorded at fair value	0.6	0.6
Liabilities:
Contingent consideration	15.5	15.1
Hybrid instrument liability	14.3	12.9
Foreign exchange contracts	1.5	2.8
Embedded derivatives in purchase and delivery contracts	0.8	0.9
Fixed price commodity contracts	0.2	0.5
Total liabilities recorded at fair value	32.3	32.2
Recurring basis | Significant Other Observable Inputs (Level 2)
Assets:
Foreign exchange contracts	0.3	0.2
Embedded derivatives in purchase and delivery contracts	0.3	0.4
Total assets recorded at fair value	0.6	0.6
Liabilities:
Foreign exchange contracts	1.5	2.8
Embedded derivatives in purchase and delivery contracts	0.8	0.9
Fixed price commodity contracts	0.2	0.5
Total liabilities recorded at fair value	2.5	4.2
Recurring basis | Significant Unobservable Inputs (Level 3)
Liabilities:
Contingent consideration	15.5	15.1
Hybrid instrument liability	14.3	12.9
Total liabilities recorded at fair value	$ 29.8	$ 28

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Changes in Level 3 Liabilities (Details) $ in Millions	9 Months Ended
	Sep. 30, 2019USD ($)
Mestrelab Research, S.L
Fair value of financial instruments
Remaining ownership percentage under options that can be exercised after 2022	49.00%
Contingent consideration
Changes in contingent consideration liabilities
Balance at the beginning of the period	$ 15.1
Current period additions	5.4
Current period adjustments	1.4
Current period settlements	(6.1)
Foreign currency effect	(0.3)
Balance at the end of the period	15.5
Hybrid instrument
Changes in contingent consideration liabilities
Balance at the beginning of the period	12.9
Current period adjustments	1.4
Balance at the end of the period	$ 14.3

Restricted Cash (Details)

Restricted Cash (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Dec. 31, 2017
Restricted Cash
Cash and cash equivalents, including restricted cash	$ 300	$ 326.3	$ 274.8	$ 328.9
ASU 2016-18 - Restricted Cash
Restricted Cash
Cash and cash equivalents, including restricted cash	$ 3.7	$ 3.9	$ 4.7	$ 3.9

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Inventories
Raw materials	$ 194.6	$ 164.5
Work-in-process	216.3	182.4
Finished goods	101.8	94.8
Demonstration units	74	67.9
Inventories	586.7	509.6
Inventory-in-transit	$ 27.8	$ 38.3

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill (Details) $ in Millions	9 Months Ended
	Sep. 30, 2019USD ($)
Goodwill
Balance at the beginning of the period	$ 275.7
Current period additions	13.9
Current period adjustments	(0.6)
Foreign currency effect	(6.7)
Balance at the end of the period	$ 282.3

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Intangible assets
Gross Carrying Amount, intangible assets subject to amortization	$ 445.9		$ 445.9		$ 403.1
Accumulated Amortization, intangible assets subject to amortization	(211.6)		(211.6)		(184.4)
Net Carrying Amount, intangible assets subject to amortization	234.3		234.3		218.7
Amortization expense related to intangible assets subject to amortization	9.2	$ 6.9	29.2	$ 21.5
Technology
Intangible assets
Gross Carrying Amount, intangible assets subject to amortization	294.4		294.4		272.6
Accumulated Amortization, intangible assets subject to amortization	(175)		(175)		(160.5)
Net Carrying Amount, intangible assets subject to amortization	119.4		119.4		112.1
Customer relationships
Intangible assets
Gross Carrying Amount, intangible assets subject to amortization	131.1		131.1		112
Accumulated Amortization, intangible assets subject to amortization	(27.1)		(27.1)		(18.1)
Net Carrying Amount, intangible assets subject to amortization	104		104		93.9
Non compete contracts
Intangible assets
Gross Carrying Amount, intangible assets subject to amortization	1.8		1.8		1.8
Accumulated Amortization, intangible assets subject to amortization	(1.8)		(1.8)		(1.8)
Trade names
Intangible assets
Gross Carrying Amount, intangible assets subject to amortization	13.2		13.2		11.6
Accumulated Amortization, intangible assets subject to amortization	(2.5)		(2.5)		(1.6)
Net Carrying Amount, intangible assets subject to amortization	10.7		10.7		10
Other
Intangible assets
Gross Carrying Amount, intangible assets subject to amortization	5.4		5.4		5.1
Accumulated Amortization, intangible assets subject to amortization	(5.2)		(5.2)		(2.4)
Net Carrying Amount, intangible assets subject to amortization	$ 0.2		$ 0.2		$ 2.7

Debt - Components (Details)

Debt - Components (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Debt
Total debt	$ 518.8	$ 341.1
Current portion of long-term debt	(0.3)	(18.5)
Total long-term debt, less current portion	518.5	322.6
US Dollar revolving loan under the 2015 Credit Agreement
Debt
Total debt	310.4	111.6
US Dollar notes under the Note Purchase Agreement
Debt
Debt, before unamortized debt issuance costs	205	220
Unamortized debt issuance costs	(0.4)	(0.5)
Other revolving loans
Debt
Total debt		2.9
Capital lease obligations and other loans
Debt
Total debt	$ 3.8	$ 7.1

Debt - Credit Agreements (Detai

Debt - Credit Agreements (Details) $ in Millions	9 Months Ended
	Sep. 30, 2019USD ($)
Revolving lines of credit
Maximum commitment	$ 736.7
US Dollar revolving loan under the 2015 Credit Agreement
Revolving lines of credit
Maximum commitment	$ 500
Maximum leverage ratio allowed	3.5
Minimum interest coverage ratio required	2.5
US Dollar revolving loan under the 2015 Credit Agreement | Minimum
Revolving lines of credit
Facility fee (as a percent)	0.10%
US Dollar revolving loan under the 2015 Credit Agreement | Maximum
Revolving lines of credit
Facility fee (as a percent)	0.20%
US Dollar revolving loan under the 2015 Credit Agreement | Greatest of prime rate, federal funds rate plus spread and adjusted LIBOR plus spread | Minimum
Revolving lines of credit
Interest rate added to base rate (as a percent)	0.00%
US Dollar revolving loan under the 2015 Credit Agreement | Greatest of prime rate, federal funds rate plus spread and adjusted LIBOR plus spread | Maximum
Revolving lines of credit
Interest rate added to base rate (as a percent)	0.30%
US Dollar revolving loan under the 2015 Credit Agreement | Prime rate
Revolving lines of credit
Variable interest rate base	prime rate
US Dollar revolving loan under the 2015 Credit Agreement | Federal Funds
Revolving lines of credit
Variable interest rate base	federal funds rate
Interest rate added to base rate (as a percent)	0.50%
US Dollar revolving loan under the 2015 Credit Agreement | Adjusted LIBOR
Revolving lines of credit
Variable interest rate base	adjusted LIBOR
Interest rate added to base rate (as a percent)	1.00%
US Dollar revolving loan under the 2015 Credit Agreement | LIBOR
Revolving lines of credit
Variable interest rate base	LIBOR
US Dollar revolving loan under the 2015 Credit Agreement | LIBOR | Minimum
Revolving lines of credit
Interest rate added to base rate (as a percent)	0.90%
US Dollar revolving loan under the 2015 Credit Agreement | LIBOR | Maximum
Revolving lines of credit
Interest rate added to base rate (as a percent)	1.30%

Debt - Revolving Loan Arrangeme

Debt - Revolving Loan Arrangements (Details) $ in Millions	Sep. 30, 2019USD ($)
Revolving lines of credit
Total Amount Committed by Lenders	$ 736.7
Outstanding Borrowings	310.4
Outstanding Letters of Credit	127.5
Total Amount Available	$ 298.8
US Dollar revolving loan under the 2015 Credit Agreement
Revolving lines of credit
Weighted Average Interest Rate (as a percent)	2.50%
Total Amount Committed by Lenders	$ 500
Outstanding Borrowings	310.4
Outstanding Letters of Credit	1.1
Total Amount Available	188.5
Alicona revolving line of credit
Revolving lines of credit
Total Amount Committed by Lenders	5.3
Total Amount Available	5.3
Other revolving loans
Revolving lines of credit
Total Amount Committed by Lenders	231.4
Outstanding Letters of Credit	126.4
Total Amount Available	$ 105

Debt - Senior Notes (Details)

Debt - Senior Notes (Details) - USD ($) $ in Millions	Jan. 18, 2019	Jan. 18, 2017	Sep. 30, 2019	Jan. 31, 2012
Debt
Principal repayment of Senior Notes			$ 15
US Dollar notes under the Note Purchase Agreement
Debt
Senior notes				$ 240
Additional aggregate principal amount that may be issued			$ 600
Minimum percentage of original aggregate principal that may be prepaid			10.00%
Prepayment price as percentage of principal amount			100.00%
Prepayment price as percentage of principal amount, in the event of a change in control			100.00%
Maximum leverage ratio allowed			3.50
Period for interest coverage ratio			1 year
Minimum interest coverage ratio required			2.50
Priority debt as a percentage of consolidated net worth			25.00%
US Dollar notes under the Note Purchase Agreement | Minimum
Debt
Written notice period to holders of the Notes			30 days
US Dollar notes under the Note Purchase Agreement | Maximum
Debt
Written notice period to holders of the Notes			60 days
3.16% Series 2012A Senior Notes, Tranche A, due January 18, 2017
Debt
Senior notes				$ 20
Interest rate, stated percentage				3.16%
Principal repayment of Senior Notes		$ 20
3.74% Series 2012A Senior Notes, Tranche B, due January 18, 2019
Debt
Senior notes				$ 15
Interest rate, stated percentage				3.74%
Principal repayment of Senior Notes	$ 15
4.31% Series 2012A Senior Notes, Tranche C, due January 18, 2022
Debt
Senior notes				$ 105
Interest rate, stated percentage				4.31%
4.46% Series 2012A Senior Notes, Tranche D, due January 18, 2024
Debt
Senior notes				$ 100
Interest rate, stated percentage				4.46%

Derivative Instruments and He_3

Derivative Instruments and Hedging Activities - Risk Management (Details) € in Millions, ¥ in Millions, £ in Millions, kr in Millions, SFr in Millions, $ in Millions, $ in Millions, $ in Millions	Sep. 30, 2019USD ($)	Sep. 30, 2019TWD ($)	Sep. 30, 2019CHF (SFr)	Sep. 30, 2019EUR (€)	Sep. 30, 2019CNY (¥)	Sep. 30, 2019SGD ($)	Sep. 30, 2019SEK (kr)	Sep. 30, 2019GBP (£)	Dec. 31, 2018USD ($)	Dec. 31, 2018CHF (SFr)	Dec. 31, 2018EUR (€)	Dec. 31, 2018CNY (¥)	Dec. 31, 2018SGD ($)	Dec. 31, 2018GBP (£)
Embedded derivative in purchase and delivery contracts
Derivative instruments and hedging activities
Notional amount of derivative sale contracts	$ 81.3								$ 113.5
Notional amount of derivative purchase contracts	7.6								6
Fixed price commodity contracts
Derivative instruments and hedging activities
Notional Amount	5.1								6.8
Not designated as hedging instruments | Foreign exchange contracts
Derivative instruments and hedging activities
Notional Amount	82.5								102.4
Fair Value of Assets	0.3								0.2
Fair Value of Liabilities	1.5								2.8
Not designated as hedging instruments | US Dollar:EUR
Derivative instruments and hedging activities
Notional Amount	20.1			€ 17.9					31.1		€ 25.4
Fair Value of Liabilities	0.6								2.1
Not designated as hedging instruments | EUR:GBP
Derivative instruments and hedging activities
Notional Amount	9.7							£ 8.1	20					£ 15.4
Fair Value of Assets	0.3
Fair Value of Liabilities									0.4
Not designated as hedging instruments | EUR:US Dollar
Derivative instruments and hedging activities
Notional Amount									8.5
Notional Amount in U.S. Dollars									8.6
Fair Value of Liabilities									0.1
Not designated as hedging instruments | YEN:CHF
Derivative instruments and hedging activities
Notional Amount	9.6		SFr 9.4						10.8	SFr 10.4
Fair Value of Liabilities	0.1								0.2
Not designated as hedging instruments | US Dollar:CHF
Derivative instruments and hedging activities
Notional Amount	7.9		SFr 7.7						11.3	SFr 11.1
Fair Value of Liabilities	0.2
Not designated as hedging instruments | CHF:USD
Derivative instruments and hedging activities
Notional Amount									2.1
Notional Amount in U.S. Dollars									2.1
Not designated as hedging instruments | CNY:EUR
Derivative instruments and hedging activities
Notional Amount				2.9	¥ 3.1
Not designated as hedging instruments | GBP:EUR
Derivative instruments and hedging activities
Notional Amount	7.2			€ 6.5					8		€ 6.9
Fair Value of Assets									0.1
Fair Value of Liabilities	0.1
Not designated as hedging instruments | USD:TWD
Derivative instruments and hedging activities
Notional Amount	6.6	$ 204
Fair Value of Liabilities	0.1
Not designated as hedging instruments | USD:CNY
Derivative instruments and hedging activities
Notional Amount	10.5				¥ 72.3				5.9			¥ 41.1
Fair Value of Assets									0.1
Fair Value of Liabilities	0.4
Not designated as hedging instruments | USD:SGD
Derivative instruments and hedging activities
Notional Amount	3.1					$ 4.2			3.1				$ 4.3
Not designated as hedging instruments | Euro:SGD
Derivative instruments and hedging activities
Notional Amount	2					$ 2.8
Not designated as hedging instruments | Euro:SEK
Derivative instruments and hedging activities
Notional Amount | kr							kr 26.7
Notional Amount in U.S. Dollars	$ 2.7
Not designated as hedging instruments | CAD:USD
Derivative instruments and hedging activities
Notional Amount									1.5
Notional Amount in U.S. Dollars									$ 1.5

Derivative Instruments and He_4

Derivative Instruments and Hedging Activities - Fair Values (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Foreign exchange contracts | Other current assets
Derivative instruments and hedging activities
Derivative assets	$ 0.3	$ 0.2
Foreign exchange contracts | Other current liabilities
Derivative instruments and hedging activities
Derivative liabilities	1.5	2.8
Embedded derivative in purchase and delivery contracts | Other current assets
Derivative instruments and hedging activities
Derivative assets	0.2	0.2
Embedded derivative in purchase and delivery contracts | Other long-term assets
Derivative instruments and hedging activities
Derivative assets	0.1	0.2
Embedded derivative in purchase and delivery contracts | Other current liabilities
Derivative instruments and hedging activities
Derivative liabilities	0.8	0.9
Fixed price commodity contracts | Other current liabilities
Derivative instruments and hedging activities
Derivative liabilities	$ 0.2	$ 0.5

Derivative Instruments and He_5

Derivative Instruments and Hedging Activities - Gains and Losses (Details) - Not designated as hedging instruments - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Derivative instruments and hedging activities
Impact on net income of unrealized gains and losses resulting from changes in fair value of derivative instruments	$ (1.1)	$ 1.1	$ 1.6	$ (6.6)
Foreign exchange contracts
Derivative instruments and hedging activities
Impact on net income of unrealized gains and losses resulting from changes in fair value of derivative instruments	(1)	1.4	1.3	(6.7)
Embedded derivative in purchase and delivery contracts
Derivative instruments and hedging activities
Impact on net income of unrealized gains and losses resulting from changes in fair value of derivative instruments	$ (0.1)			1.3
Fixed price commodity contracts
Derivative instruments and hedging activities
Impact on net income of unrealized gains and losses resulting from changes in fair value of derivative instruments		$ (0.3)	$ 0.3	$ (1.2)

Provision for Income Taxes (Det

Provision for Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Provision for Income Taxes
Income tax expense (benefit)	$ 21.7	$ 21.2	$ 40	$ 41.4
Effective tax rates (as a percent)	26.10%	32.40%	23.60%	28.70%
Unrecognized tax benefits, excluding penalties and interest	$ 6.5		$ 6.5		$ 6.5
Accrued interest and penalties related to uncertain tax positions	0.3		0.3		$ 0.2
Penalties and interest (benefit) expense relating to unrecognized tax benefits	$ 0.1	$ 0	$ 0.1	$ 0
Statutory tax rate (as a percent)			21.00%
Germany and Switzerland
Provision for Income Taxes
Change in tax rates (as a percent)			5.30%
Germany
Provision for Income Taxes
Statutory tax rate (as a percent)			30.00%
Switzerland
Provision for Income Taxes
Statutory tax rate (as a percent)			20.00%

Commitments and Contingencies -

Commitments and Contingencies - Letters of Credit and Guarantees (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Letters of Credit and Guarantees
Bank guarantees primarily for customer advances	$ 127.5
Revolving Loans
Letters of Credit and Guarantees
Bank guarantees primarily for customer advances	$ 127.5	$ 138.3

Commitments and Contingencies_2

Commitments and Contingencies - Litigation and Related Contingencies (Details) $ in Millions	Sep. 25, 2019product	Sep. 30, 2019USD ($)	Dec. 31, 2018USD ($)
Commitments and Contingencies
Number of product category | product	1
Accruals for potential contingencies | $		$ 0	$ 0

Commitments and Contingencies_3

Commitments and Contingencies - Governmental Investigations (Details) - USD ($)	Jun. 16, 2019	Sep. 30, 2019	Dec. 31, 2018
Governmental Investigations
Accruals for potential contingencies		$ 0	$ 0
Governmental Investigations
Governmental Investigations
Accruals for potential contingencies		$ 0	$ 0
Legal | Korea | Governmental Investigations
Governmental Investigations
Fine amount to be imposed	$ 20,000

Leases - Lease Cost (Details)

Leases - Lease Cost (Details) - USD ($) $ in Millions	Jan. 01, 2019	Sep. 30, 2019	Sep. 30, 2019
Leases and Lease cost
Practical expedients	true
Components of lease cost
Amortization of right-of-use assets		$ 0.1	$ 0.2
Total finance lease cost		0.1	0.2
Operating lease cost		6.1	18.8
Short term lease cost		0.5	1.6
Variable lease cost		1	2.7
Sublease income		(0.3)	(0.9)
Total lease cost		$ 7.4	$ 22.4
ASU 2016-02
Leases and Lease cost
Lease assets	$ 75.5
Lease liabilities	$ 77.9

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information (Details) $ in Millions	Sep. 30, 2019USD ($)
Operating Leases
Operating lease assets, net	$ 68.9
Other current liabilities	$ 20.4
Other current liabilities (Balance sheet location)	Us-gaap:OtherLiabilitiesCurrent
Operating lease liability - long term	$ 50.7
Finance Leases
Property, plant and equipment, net	$ 1.5
Property, plant and equipment, net (Balance sheet location)	Us-gaap:PropertyPlantAndEquipmentNet
Current portion of long-term debt	$ 0.4
Current portion of long-term debt (Balance sheet location)	Us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
Long-term debt	$ 1
Long-term debt (Balance sheet location)	Us-gaap:LongTermDebtAndCapitalLeaseObligations
Weighted average remaining lease term
Operating leases	5 years 2 months 12 days
Finance leases	3 years 6 months
Weighted average discount rate
Operating leases	2.50%
Finance leases	2.80%

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) $ in Millions	9 Months Ended
	Sep. 30, 2019USD ($)
Supplemental cash flow information related to leases
Operating cash flows from operating leases	$ 17.7
Financing cash flows from finance leases	0.2
Right-of-use assets obtained in exchange for lease liabilities
Operating leases	16.4
Finance leases	$ 0.8

Leases - Future Minimum Lease P

Leases - Future Minimum Lease Payments (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Operating leases
2019 (excluding the nine months ended September 30, 2019)	$ 5.9
2020	20.6	$ 19.1
2021	15.2	13.7
2022	9.7	9.3
2023	7.6	7.3
Thereafter	16.7	18.4
Total	75.7	93.1
Less: Imputed interest	(4.6)
Total lease liabilities	71.1
Finance leases
2019 (excluding the nine months ended September 30, 2019)	0.1
2020	0.5	0.1
2021	0.4	0.1
2022	0.3
2023	0.2
Total	1.5	$ 0.2
Imputed interest	(0.1)
Total lease liabilities	$ 1.4

Leases - Minimum Lease Commitme

Leases - Minimum Lease Commitments Under Prior Guidance (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Operating leases
2019		$ 25.3
2020	$ 20.6	19.1
2021	15.2	13.7
2022	9.7	9.3
2023	7.6	7.3
Thereafter	16.7	18.4
Total	75.7	93.1
Minimum commitments for finance leases under prior lease guidance
2020	0.5	0.1
2021	0.4	0.1
2022	0.3
2023	0.2
Total	$ 1.5	$ 0.2

Shareholders' Equity - Share Re

Shareholders' Equity - Share Repurchase and Dividends (Details) - USD ($) $ / shares in Units, $ in Millions	Feb. 22, 2016	Sep. 30, 2019	Sep. 30, 2018	Jun. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Oct. 30, 2019	May 31, 2019
Shareholders' Equity
Aggregate cost of common stock repurchased during the period			$ 0.1	$ 0.1
Remaining authorization amount for repurchase of common stock							$ 157.7
Dividend declared per common share (in dollars per share)	$ 0.04	$ 0.04	$ 0.04		$ 0.12	$ 0.12
Target dividend per annum (in dollars per share)					$ 0.16
May 2017 Repurchase Program
Shareholders' Equity
Common stock repurchased during the period (in shares)			0			0
May 2019 Repurchase Program
Shareholders' Equity
Amount approved for repurchase of common stock								$ 300
Common stock repurchased during the period (in shares)		1,022,469			3,323,104
Aggregate cost of common stock repurchased during the period		$ 42.3			$ 142.3

Shareholders' Equity - Comprehe

Shareholders' Equity - Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Summary of comprehensive income (loss)
Consolidated net income	$ 61.5	$ 44.2	$ 129.2	$ 103.1
Foreign currency translation adjustments	(36.5)	(2.5)	(38.9)	(17.1)
Pension liability adjustments, net of tax	1.1	0.2	1.7	2.3
Net comprehensive income (loss)	26.1	41.9	92	88.3
Less: Comprehensive income (loss) attributable to noncontrolling interests	0.2	0.5	1	0.9
Less: Comprehensive income (loss) attributable to redeemable noncontrolling interest	(1.2)		(1.8)
Comprehensive income (loss) attributable to Bruker Corporation	$ 27.1	$ 41.4	$ 92.8	$ 87.4

Shareholders' Equity - Accumula

Shareholders' Equity - Accumulated Other Comprehensive Income (Loss) (Details) $ in Millions	9 Months Ended
	Sep. 30, 2019USD ($)
Summary of the components of accumulated other comprehensive income, net of tax
Balance at beginning of period	$ 905.1
Balance at end of period	854.7
Accumulated Other Comprehensive Income (Loss)
Summary of the components of accumulated other comprehensive income, net of tax
Balance at beginning of period	17
Other comprehensive income (loss) before reclassifications	(37)
Amounts reclassified from other comprehensive income (loss), net of tax of $0.1 million	1.2
Net current period other comprehensive income (loss)	(35.8)
Balance at end of period	(18.8)
Amount from reclassification, tax	0.2
Foreign Currency Translation
Summary of the components of accumulated other comprehensive income, net of tax
Balance at beginning of period	46.9
Other comprehensive income (loss) before reclassifications	(37.6)
Net current period other comprehensive income (loss)	(37.6)
Balance at end of period	9.3
Pension Liability Adjustment
Summary of the components of accumulated other comprehensive income, net of tax
Balance at beginning of period	(29.9)
Other comprehensive income (loss) before reclassifications	0.6
Amounts reclassified from other comprehensive income (loss), net of tax of $0.1 million	1.2
Net current period other comprehensive income (loss)	1.8
Balance at end of period	$ (28.1)

Other Charges (Gain), Net - Com

Other Charges (Gain), Net - Components (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Other Charges (Gain), Net
Information technology transformation costs	$ 0.8	$ 1.1	$ 2.8	$ 3.5
Restructuring charges	(7.4)	2	(5.5)	5.9
Acquisition-related charges	0.9	1.2	5.9	2.3
Other	0.4	0.9	1.7	3.5
Other charges (gain), net	$ (5.3)	$ 5.2	$ 4.9	$ 15.2

Other Charges (Gain), Net - Res

Other Charges (Gain), Net - Restructuring Plans (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Restructuring charges
Restructuring expenses	$ (6.8)		$ 2.5	$ (1.4)	$ 6.7
Sale of building
Restructuring charges
Restructuring expenses		$ (7.8)		(7.8)
Costs of product revenue
Restructuring charges
Restructuring expenses	0.6		0.5	4.1	0.8
Other charges (gain), net
Restructuring charges
Restructuring expenses	$ (7.4)		$ 2	$ (5.5)	$ 5.9

Other Charges (Gain), Net - R_2

Other Charges (Gain), Net - Restructuring Reserves (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Changes in the restructuring reserves
Balance at the beginning of the period			$ 7.3
Restructuring charges	$ (6.8)	$ 2.5	(1.4)	$ 6.7
Cash payments			(5.3)
Other, non-cash adjustments and foreign currency effect			4.1
Balance at the end of the period	4.7		4.7
Severance
Changes in the restructuring reserves
Balance at the beginning of the period			2
Restructuring charges			4.1
Cash payments			(4.1)
Other, non-cash adjustments and foreign currency effect			(0.5)
Balance at the end of the period	1.5		1.5
Exit Costs
Changes in the restructuring reserves
Balance at the beginning of the period			1.4
Restructuring charges			(5.9)
Cash payments			(1.2)
Other, non-cash adjustments and foreign currency effect			5.9
Balance at the end of the period	0.2		0.2
Provisions for Excess Inventory
Changes in the restructuring reserves
Balance at the beginning of the period			3.9
Restructuring charges			0.4
Other, non-cash adjustments and foreign currency effect			(1.3)
Balance at the end of the period	$ 3		$ 3

Interest and Other Income (Ex_3

Interest and Other Income (Expense), Net (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Interest and Other Income (Expense), Net
Interest expense, net	$ (4.7)	$ (2.3)	$ (11.5)	$ (8.3)
Exchange (losses) gains on foreign currency transactions	0.7	(0.6)	(0.7)	(1.6)
Pension components	(0.6)	(0.9)	(1.8)	(2.2)
Other		0.1		0.6
Interest and other income (expense), net	$ (4.6)	$ (3.7)	$ (14)	$ (11.5)

Business Segment Information (D

Business Segment Information (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)segment	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)
Business segment information
Number of reportable segments | segment			2
Revenue	$ 521.1	$ 466.6	$ 1,472.7	$ 1,342
Operating Income (loss)	87.8	69.1	183.2	156
Assets	2,352.1		2,352.1		$ 2,128.6
Eliminations
Business segment information
Revenue	(3.2)	(1.4)	(10.5)	(3.7)
Corporate, eliminations and other
Business segment information
Operating Income (loss)	0.1	0.1		0.2
Assets	(3.6)		(3.6)		(5.2)
BSI | Operating segments
Business segment information
Revenue	471.8	417.1	1,331	1,206.5
Operating Income (loss)	84	63.6	173.3	146.5
Assets	2,296.5		2,296.5		2,100.6
BEST | Operating segments
Business segment information
Revenue	52.5	50.9	152.2	139.2
Operating Income (loss)	3.7	$ 5.4	9.9	$ 9.3
Assets	$ 59.2		$ 59.2		$ 33.2

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event € in Millions, $ in Millions	Oct. 31, 2019USD ($)	Oct. 01, 2019USD ($)	Oct. 01, 2019EUR (€)
Land and Buildings in Billerica, MA
Subsequent Event
Purchase of land and buildings	$ 12.3
EPR
Subsequent Event
Purchase price		$ 9.3	€ 8.5